WO2010040545A1 - Proteolytically stable antibody formats - Google Patents
Proteolytically stable antibody formats Download PDFInfo
- Publication number
- WO2010040545A1 WO2010040545A1 PCT/EP2009/007277 EP2009007277W WO2010040545A1 WO 2010040545 A1 WO2010040545 A1 WO 2010040545A1 EP 2009007277 W EP2009007277 W EP 2009007277W WO 2010040545 A1 WO2010040545 A1 WO 2010040545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- polypeptide
- domain
- antibody construct
- variable
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 184
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 175
- 229920001184 polypeptide Polymers 0.000 claims abstract description 166
- 239000000427 antigen Substances 0.000 claims abstract description 72
- 102000036639 antigens Human genes 0.000 claims abstract description 72
- 108091007433 antigens Proteins 0.000 claims abstract description 72
- 230000027455 binding Effects 0.000 claims abstract description 60
- 239000012634 fragment Substances 0.000 claims abstract description 38
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 38
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 38
- 239000002157 polynucleotide Substances 0.000 claims abstract description 37
- 239000013598 vector Substances 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 244000005700 microbiome Species 0.000 claims abstract description 15
- -1 carrier Substances 0.000 claims abstract description 14
- 239000000872 buffer Substances 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000003381 stabilizer Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 103
- 241000196324 Embryophyta Species 0.000 claims description 60
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 239000000178 monomer Substances 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 241000223924 Eimeria Species 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 10
- 238000003776 cleavage reaction Methods 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 240000004713 Pisum sativum Species 0.000 claims description 9
- 235000010582 Pisum sativum Nutrition 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 241000287828 Gallus gallus Species 0.000 claims description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 241000186362 Mycobacterium leprae Species 0.000 claims description 7
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 7
- 241000315672 SARS coronavirus Species 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 241000223932 Eimeria tenella Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 238000002823 phage display Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241000195493 Cryptophyta Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 4
- 240000002791 Brassica napus Species 0.000 claims description 4
- 240000008067 Cucumis sativus Species 0.000 claims description 4
- 240000005979 Hordeum vulgare Species 0.000 claims description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 3
- 241000195585 Chlamydomonas Species 0.000 claims description 3
- 235000009849 Cucumis sativus Nutrition 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 241000235346 Schizosaccharomyces Species 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 3
- 235000007244 Zea mays Nutrition 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 230000009545 invasion Effects 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 231100000255 pathogenic effect Toxicity 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 abstract description 12
- 235000001014 amino acid Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 24
- 239000000539 dimer Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 244000045947 parasite Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 210000001938 protoplast Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010023076 Isosporiasis Diseases 0.000 description 3
- 241000243985 Onchocerca volvulus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004913 chyme Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 241000207746 Nicotiana benthamiana Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000004938 Trematode Infections Diseases 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010014881 enterobiasis Diseases 0.000 description 2
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000003250 oocyst Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 208000004441 taeniasis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 208000003982 trichinellosis Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000203022 Acholeplasma laidlawii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000223838 Babesia bovis Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 101000972350 Bombyx mori Lebocin-4 Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010051226 Campylobacter infection Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009344 Clonorchiasis Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 201000000077 Cysticercosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 244000127993 Elaeis melanococca Species 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 208000000807 Gnathostomiasis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 244000299507 Gossypium hirsutum Species 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 241000222736 Leishmania tropica Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000665629 Linum flavum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000520674 Mesocestoides corti Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 241000204028 Mycoplasma arginini Species 0.000 description 1
- 241000202956 Mycoplasma arthritidis Species 0.000 description 1
- 241000202938 Mycoplasma hyorhinis Species 0.000 description 1
- 241000202894 Mycoplasma orale Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101710202365 Napin Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241001672171 Taenia hydatigena Species 0.000 description 1
- 241000244154 Taenia ovis Species 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000223097 Trypanosoma rangeli Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000004927 campylobacteriosis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000008576 dracunculiasis Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 206010016235 fasciolopsiasis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 244000000036 gastrointestinal pathogen Species 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 201000000128 gnathomiasis Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 208000010544 human prion disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000007188 hymenolepiasis Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 201000001198 metagonimiasis Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 208000009920 trichuriasis Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- an antibody “Fab” fragment fragment antigen binding is the region of an antibody composed of a complete light chain linked to the N-terminal part of a heavy chain, consisting of the variable region (V H ) and one constant domain (C N I ).
- the Fab fragment may be generated e.g. by papain hydrolysis of an antibody.
- the other part of an antibody is called “Fc” region (fragment crystallizable region) or “Fc” fragment.
- the Fc region is the tail region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system.
- scFv single chain variable fragment
- An ScFv is a fusion protein of the variable regions of the heavy and light chains of an immunoglobulin in a single polypeptide chain using a linker, essentially encompassing a truncated Fab fragment antigen binding site.
- Gene technology methods such as phage display allow the production of a recombinant single-chain variable fragment.
- Phage display is a standard technique for the presentation of distinct peptides, polypeptides or proteins on the surface of bacteriophages. It allows the identification of the exposed peptides, polypeptides or proteins via their binding properties. The technique is used for the establishment of libraries of peptide, polypeptide or protein variants such as different antibody fragments.
- mammals such as mice are immunized against the antigen of interest and lymphocytes are isolated, e.g. from the spleen. Then, mRNA is isolated, and a cDNA library is generated by cloning the cDNA into a phage display vector.
- the phage display library generated in this way contains recombinant scFv antibody fragments.
- the random library is screened for protein-protein interactions, e.g. for their antigen binding specificities. Interacting clones of the library are enriched, and the phagemid DNA from individual clones can be isolated and sequenced. Using recombinant antibodies has significant advantages when compared to conventional antibodies and therefore their use is becoming more common.
- Active immunization entails the introduction of an antigen into the body, which causes the body itself to generate immunity against the target. Active immunization is normally used for prophylaxis, like vaccination, but not for treatment of infections. Passive immunization is where pre-made elements, like antibodies, of the immune system are transferred to an organism. This method of immunization begins to work very quickly, but it is short lasting, because the antibodies are naturally broken down, and if there are no B cells to produce more antibodies, they will disappear.
- Passive immunization can be used if there has been a recent outbreak of a particular disease or as an emergency treatment to poisons (for example, for tetanus).
- One of the drawbacks of passive immunization is the poor stability of most antibodies.
- oral administration is not very effective, because the antibodies are denatured and degraded in the stomach due to proteolytic enzymes and the acidic environment.
- oral administration is the cheapest and most convenient method, particularly for the immunization of production animals.
- a further object of the present invention is to provide polynucleotides and/or vectors encoding these polypeptides, prokaryotic or eukaryotic host cells comprising these polynucleotides, vectors and/or polypeptides, transgenic plants, parts thereof or microorganisms containing the polynucleotides, vectors and/or polypeptides of the present invention, as well as compositions comprising said antigen-binding polypeptides.
- the present invention relates to a polypeptide, or a dimer of polypeptides or an antibody construct whereby each monomer polypeptide chain comprises a constant domain of an immunoglobulin light chain (Q.) and a variable domain of an immunoglobulin light chain (V L ) linked via a polypeptide linker to a variable domain of an immunoglobulin heavy chain (V H ), wherein the V H domain of the first monomer associates with the V L domain of the second monomer to form a first antigen binding site; and the V H domain of the second monomer associates with the V L domain of the first monomer to form a second antigen binding site; whereby the polypeptide linker connecting the V H and V L domains of the same monomer is of such a length that the adjacent V H and V L domains of the same monomer are incapable of associating with each other to form an antigen binding site.
- the first aspect of the present invention provides an antibody construct, comprising
- variable light domain is connected to the constant light domain
- variable heavy domain is connected to the variable light domain via a linker, wherein said linker consists of 0-12 am ino acids, whereby the variable light domain of each monomer is operatively associated with the variable heavy domain of the other monomer, and the variable light domain of each monomer forms an antigen binding site with the variable heavy domain of the other monomer.
- the invention preferably provides a dimer of polypeptides, wherein each monomer comprises three domains and a linker ( Figure 3).
- the three domains are a constant domain of a light chain, which can be either a kappa domain or a lambda domain, a variable domain of a light chain and a variable domain of a heavy chain.
- the constant domain of a light chain is connected to the variable domain of a light chain.
- the variable domain of a light chain is connected to the variable domain of a heavy chain via a short linker, although it is also intended that the domains can be connected directly without a linker at all (linker of 0 amino acids). Both monomers form a dimer, preferred via a disulfide bond between both constant domains of the light chains.
- Diabodies consisting of cross-paired small variable antibody fragments are known in the prior art (Holliger et al, 1993, Proc Natl Acad Sci, 15;90 (14):6444-8).
- the major benefit of cross-pairing variable regions is that dimerization provides two antigen-binding domains, and therefore provides the option of bivalent or bi-specific antigen binding, whereby the antibody fragment has two antigen binding regions that can be targeted to either the same or different antigen targets.
- diabodies are only held together as dimers by non-covalent and relatively limited binding forces, resulting in sufficient dimer-binding for biological activity, although poor long term stability in storage or in vivo during treatment.
- Fc domains demonstrate another significant disadvantage in their susceptibility to proteolytic cleavage.
- the Fc domain is linked to the light chain fragment by a hinge region, a region which can be susceptible to protease attack, as seen in its susceptibility to Papain digestion, and therefore shows a greater risk of low stability.
- the heavy chain of an immunoglobulin molecule can contain approximately 450 amino acids, presenting a significant increase in size to the antibody fragment when an Fc-fragment is fused. The large size leads to multiple disadvantages.
- E ⁇ xpression of a scFv DNA construct fused to the heavy chain Fc region becomes more difficult to express in comparison to DNA open reading frames of shorter length.
- Production of recombinant antibodies commonly takes place through the expression of recombinant constructs encoding the antibody fragments in host cells. Larger antibody constructs are typically more lowly expressed, therefore limiting production capacity. Larger proteins are also more likely to be insoluble once expressed, particularly in bacterial expression systems, therefore requiring additional preparation work such as inclusion body preparation, extraction and re-solubilisation of the antibodies. Large antibodies are also clearly disadvantageous in the treatment of cancer, whereby smaller scFv antibody fragments have been shown to be better able in penetrating tumour mass and have shown improved localisation at tumour sites.
- the large Fc region could also show a greater likelihood of protease degradation due to the presence of potential protease recognition sites.
- Large protein fragments are more likely to be targeted by proteases, thus reducing the effective half-life of the antibody in vivo.
- the inclusion of larger proteins in pharmaceutical compositions is also disadvantageous in comparison to small proteins. Solubility and stability issues are of huge importance in producing biological pharmaceutical preparations, thus the reduction of antibody size is likely to play a significant role in enhancing their application in pharmaceutical products.
- the presence of a heavy-chain Fc region could be more likely to induce a potentially dangerous immune reaction when administered in vivo, as the large Fc region is a more significant and accessible target for the host immune response and could lead to allergic reactions.
- the present invention provides a novel antibody format comprising a dimer of polypeptides, with a cross-pairing antigen-binding structure, comprising cross-paired variable fragments of light and heavy chains, with additional constant light domains to facilitate enhanced dimerization.
- the format of the invention is surprisingly superior when compared to all formats disclosed in the prior art.
- the use of Q. domains solves many of the problems inherent in using Fc fragments, such as providing a smaller molecule that with improved expression levels and solubility, and additionally leads to surprising advantages such as enhanced binding strength and stability. It was until now unknown whether the Q. domain could solve the problems inherent in scFv or scFv-Fc fragments.
- scFv constructs in particular have demonstrated problems with stability, solubility, expression, aggregation, breakdown products, and overall manufacturability. Additionally, incorporation of scFv molecules into otherwise stable recombinant antibody products often imparts these generally undesirable traits to the new recombinant design.
- polypeptides of the present invention showed an enhanced stability in comparison with the antibody formats known in the prior art, especially diabodies or Fc-fused-diabody constructs. It was unexpected that the embodiments of the present invention would lead to antibody constructs stable enough to overcome the problems mentioned above.
- the saving of time, material, work steps, costs and resources are also advantages of the present invention.
- the production of the polypeptides of the present invention is distinguished by a better yield and therefore price-reduction. Due to the shorter length of the Q. domain in comparison to the Fc-fused-diabodies, expression levels of the recombinant protein are higher and therefore more efficient and cost-effective Furthermore, it was surprising that a small linker consisting of 12 or less amino acids could be used to connect V L and V H . The use of a small linker prevents the assembling of V L and V H within the same chain. Thus each antigen binding site is formed by V L of one chain and V H of the other chain. Surprisingly these antigen binding sites lead to a higher affinity between antibody and antigen.
- domain-containing antibody constructs of the present invention would result in high expression and solubility and therefore high activity in plant expression systems.
- High expression levels in plants results in an enormous advantage in regards to providing the antibody to humans or animals in the plant form, without requiring additional separation, purification and preparation steps.
- antibodies directed against bird, preferably chicken, pathogens could be expressed in plants and administered to chickens as fodder.
- cross-pairing scFv fragments with Q. domains leads to surprising synergistic effects.
- the cross-pairing of the scFv fragments combined with the dimerization of the Q. domains lead to enhanced dimer formation and stability, more so than if either factor had been applied in isolation.
- the effective dimerization provided by the Q. domains, in concert with the cross-pairing scFv fragments, produces greater than additive effects.
- Polypeptides includes all polypeptides as described below. The basic structure of polypeptides is well known and has been described in innumerable textbooks and other publications in the art. In this context, the term is used herein to refer to any peptide or protein comprising amino acids joined to each other in a linear chain by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types.
- polypeptides often contain amino acids other than the 20 amino acids at commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes such as glycosylation and other post-translational modifications, or by chemical modification techniques which are well known in the art. Common modifications include glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP- ribosylation, and these and others are described in most basic texts, such as, for instance, I. E. Creighton, Proteins- Structure and Molecular Properties, 2nd Ed., W. H. Freeman and Company, New York, 1993.
- polypeptides are not always entirely linear.
- polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslational events, including natural processing events and events brought about by human manipulation which do not occur naturally.
- Circular, branched and branched circular polypeptides may be synthesized by non-translational natural processes and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini.
- polypeptides made by expressing a cloned gene in a host for instance, the nature and extent of the modifications in large part will be determined by the host cell posttranslational modification capacity and the modification signals present in the polypeptide amino acid sequence.
- glycosylation often does not occur in bacterial hosts such as E. cxili. Accordingly, when glycosylation is desired, a polypeptide should be expressed in a glycosylating host, generally a eukaryotic cell.
- the "antigen-binding” refers to that portion of a polypeptide and/or antibody which contains the amino acid residues that interact with an antigen and confer on the antibody its specificity and affinity for the antigen.
- the term "antigen-binding polypeptide” as used herein means a polypeptide or protein which, according to the invention, specifically binds to an antigen.
- the term “specific binding”, “binding specificity, “as used herein means that the polypeptide of the present invention does not show any significant binding other molecules. Usually this binding is reversible and/or non-covalent.
- the term “heavy chain” or “light chain” as used herein means the conventional antibody polypeptide heavy chain (H) or light chain (L), respectively.
- single chain variable fragment or “single-chain antibody” or “single-chain fragment 1 ' as used herein means any polypeptide comprising the variable region of a heavy chain, the variable region of a light chain and a linking peptide between the variable region of the heavy and the light chain, resulting in a single chain Fv or "scFv".
- a "domain" of a polypeptide or protein is a discrete part of an amino acid sequence that can be equated with a particular function.
- the new antigen-binding polypeptide and/or the antibody construct can be used in the treatment, prophylaxes, aftercare, follow-up treatment or diagnosis for all disease that can be treated with antibodies.
- Diseases in terms of the invention are viral infectious diseases, bacterial infectious diseases, parasitic infectious diseases, fungal infectious diseases, prion infectious diseases, tumor diseases and/or autoimmune diseases. All diseases that are caused by an infections agent or a pathogen can be treated and/or prevented with the polypeptides and/or antibody constructs of the invention.
- infectious agent and "pathogen” denotes both microbes and parasites.
- a “microbe” includes viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganisms.
- a “parasite” denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which are susceptible to antibody-induced clearance or lytic or phagocytic destruction, such as malarial parasites, spirochetes, and the like.
- infectious agents include, for example, a fungus, virus, parasite, bacterium, protozoan, or mycoplasm.
- the fungus may be from the species of Microsporum, Trichophyton, Epidemnophyton, Sporothrix schenckii, Cyiptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, or Candida albicans.
- the virus may be from the species of human immunodeficiency virus (HIV), herpes virus, cytomegalovirus, rabies virus, influenza virus, hepatitis B virus, SARS coronavirus, Sendai virus, feline leukemia virus, Reo virus, polio virus, human serum parvo-like virus, simian virus 40, respiratory syncytial virus, mouse mammary tumor virus, Varicella-Zoster virus, Dengue virus, rubella virus, measles virus, adenovirus, human T-cell leukemia viruses, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocytic choriomeningitis virus, wart virus and blue tongue virus.
- HCV human immunodeficiency virus
- herpes virus cytomegalovirus
- rabies virus influenza virus
- hepatitis B virus SARS coronavirus
- Sendai virus
- the bacterium may be, for example, Anthrax bacillus, Streptococcus agalactiae, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Mycobacterium leprae, Brucella abortus, and Tetanus toxin.
- the parasite may be a helminth or a malarial parasite.
- polypeptides and/or the antibody constructs of the invention is especially advantageous for AIDS, AIDS related complex, chickenpoxx, common cold, cytomegalovirus infection, Colorado tick fever -dengue fever, ebola hemorrhagic fever, hand, foot and mouth disease, hepatitis, herpes simplex, herpes zoster, HPV, influenza, lassa fever, measles, marburg hemorrhagic fever, infectious mononucleosis, mumps, norovirus, poliomyelitis, Progressive multifocal leukencephalopathy, rabies, rubella, smallpox, viral encephalitis, viral gastroenteritis, viral meningitis, viral pneumonia, West nile disease, yellow fever, anthrax, bacterial meningitis, botulism, brucellosis, campylobacteriosis, cat scratch disease, cholera, diphtheria, epidemic typhus, gonorrhea, impetig
- a third aspect of the present invention relates to an antibody construct, comprising
- variable domains of a light chain wherein each variable domain of a light chain is associated with a constant domain of a light chain
- a fourth aspect of the present invention relates to an antibody construct, comprising
- variable light domain is associated with the constant domain
- variable heavy domain is connected to the variable light domain via a linker, wherein said linker consists of 0-12 amino acids, whereby the variable light domain of each chain is operatively associated with the variable heavy domain of the other chain.
- the present invention provides a polypeptide and/or antibody construct that exhibits all the elements and features of the four aspects of the invention. Such an embodiment is especially effective in providing a solution to the task of the present invention.
- the present invention relates to the polypeptide and/or antibody construct, wherein both constant domains of a light chain are kappa domains. Surprisingly the use of kappa chains resulted in high bioactivity and thus greater efficiency. The use of kappa chains is also advantageous because the transient expression of these antibody constructs is surprisingly high. Such constructs are known as Di-kappa-bodies. Also preferred is the polypeptide and/or the antibody construct, wherein both constant domains of a light chain are lambda domains.
- lambda chains resulted in a surprisingly high activity in vifro and in vivo.
- a high activity is especially advantageous for therapeutical application because a lower dose can be used which prevents side effects.
- the polypeptide and/or the antibody construct of the invention wherein the constant domains are connected, preferred covalently, especially via a disulfide bridge. Dimers that are formed by non-covalent association often dissociate; the invention solves this problem by introducing a disulfide bond, preferably between Q. domain fragments. Analyses of molecular forms proved that the polypeptides and/or antibodies of the present invention do not dissociate and are therefore dime ⁇ ' c.
- the disulfide bridge leads to a much higher stability, especially proteolytic stability, of the fragment.
- the antigen-binding polypeptide and/or the antibody construct bearing a disulfide bridge are more resistant to for example enzymatic cleavage. This leads to a higher half-life in an organism, which results in a higher efficacy. Poor stability can affect the ability of an antibody or antibody domain to fold property when expressed in various cellular systems, e.g., in bacterial or mammalian expression systems.
- polypeptide and/or the antibody construct of the invention wherein the constant domains are connected via hydrophobic interaction. Hydrophobic interaction can be superior to covalent associations under certain circumstances.
- a person skilled in the art knows that there are several ways to connect two chains of a polypeptide. Disulfide bridges and hydrophobic interactions are preferred embodiments of the invention, however it is understood that any kind of connection, covalent or non- covalent, known in the state of art can be used to connect the polypeptide of the invention. A skilled person knows that which connection or association is suited best for a certain condition.
- Another preferred embodiment of the invention is the polypeptide and/or the antibody construct, wherein said linker is not susceptible to protease cleavage.
- linkers in antibody constructs are often a target for protease cleavage.
- the special linkers of the invention are resistant to enzymatic cleavage, especially protease cleavage.
- a linker comprising the amino acid sequence of Seq. ID NO 41 (GGSGGS). The use of this linker resulted in an extremely high stability of the antibody construct.
- the antibody constructs of the invention are more stable and therefore superior compared to antibodies in the state of art.
- amino acids have analogous physicochemical properties so that these amino acids advantageously can be replaced by each other.
- these include the group of nonpolar (hydrophobic) amino acids (a) glycine, alanine, valine, leucine and/or isoleucine; or the hydroxy amino acids (b) serine, threonine and/or tyrosine, the amides of amino dicarboxylic acids (c) asparagine and glutamine, the amino dicarboxylic acids (d) aspartic acid and glutamic acid; the basic amino acids (e) lysine, arginine and/or ornithine as well as the group of aromatic amino acids (f) phenylalanine, tyrosine and/or tryptophan.
- nonpolar amino acids a) glycine, alanine, valine, leucine and/or isoleucine
- hydroxy amino acids b) serine, threonine and/or tyrosine
- Another aspect is the replacement of amino acids by structural similar amino acids.
- this is the case in the group with a ⁇ -functional group (g) cysteine, methionine, serine, ⁇ - aminobutyric acid and selenocysteine as well as the turn-inducing group (h) praline, 1 -aminc-2- carboxy cyclohexane, pipecolic acid and an ortho-aminobenzoic acid.
- Amino acids within one and the same group (a- h) can be replaced with one another.
- peptide sequences will have a sufficient homology to be an analogous to an amino acid sequence of the peptides of the invention.
- the amino acids can be replaced by modified amino acids or specific enantiomers.
- the outcome produced with the peptides or nucleic acids of the invention may also be produced with the functionally analogous/equivalent means.
- a person skilled in the art can therefore easily and quickly verify whether a functionally analogous/equivalent sequence provided by them is covered by the invention.
- the functionally analogous sequence is covered by the invention if it may be used for solving the problem of the invention and if the solving of the problem of the invention can be earned out in essentially the same way as is claimed by the invention.
- the amino acid molecule has at least 60%, preferably 70%, more preferably 80%, especially preferably 90% homology to the amino acid molecule of Seq. ID NO 41.
- the linker of the invention for the preparation of an antibody construct. Surprisingly this linker can not only be used in the antibody constructs of the invention but also in other antibody constructs known in the prior art. It was very surprising that by the use of the linker in known antibody constructs, these constructs become more stable, more specific and therefore more effective.
- the invention relates to the polypeptide and/or the antibody construct, wherein said polypeptide and/or antibody construct is monospecific.
- the present invention relates to the polypeptide and/or the antibody construct, wherein said polypeptide and/or an antibody construct is bispecific.
- a bispecific protein dimer comprising one monomer, wherein said V H domain of specificity A is linked to a light chain of specificity B, and the second monomer, wherein said V H domain of specificity B is linked to a light chain of specificity A.
- a monospecific or a bispecific antibody construct is suited for any given application depends on the target.
- One benefit of the bispecific antibody construct is that it is possible for such an antibody to simultaneously bind two different antigens, for example a bispecific antibody can bind to a cytotoxic cell and a target cell at the same time.
- Monospecific antibodies bind to the same antigen sequence with both antigen binding sites; therefore they can neutralize or eliminate the antigen in a very effective way.
- the use of monospecific antibodies is also preferred in diagnostics.
- the polypeptide and/or the antibody construct wherein said linker is selected from the group consisting of a GS-linker, a yoHinker and/or a linker with the amino acid sequence GGSGGS.
- said linker is selected from the group consisting of a GS-linker, a yoHinker and/or a linker with the amino acid sequence GGSGGS.
- the GGSGGS linker is relatively inflexible, which is advantageous for the conformation of the polypeptide and/or antibody construct of the invention. It is understood, that a person skilled in the art knows that certain amino acids can be replaced by others.
- polypeptide and/or the antibody construct comprising the amino acid sequence selected from the group comprising Seq. ID N0 1
- Antibody constructs comprising sequence ID NO 2 and 3 exhibited a good activity against HIV.
- the expression levels of dimers consisting of two chains, each comprising Seq. ID NO 2 and/or 3 were surprisingly high. Additionally antibody constructs comprising Seq. ID NO 3 were extremely stable, even under reducing conditions most of the polypeptides were present in the dimeric form.
- Seq. ID NO 4 in an antibody construct led to a high specificity against the Eimeria antigen, whereas the use of Seq. ID NO 5 and 6 was superior for the binding of HIV.
- polypeptide and/or an antibody construct wherein at least one variable domain of a light chain V L comprises the amino acid sequence selected from the group comprising Seq. ID NO 7
- V L domain comprising Seq. ID NO 7 was advantageous in antibody constructs directed against Eimeria.
- V L domains comprising Seq. ID NO 8 and/or Seq. ID NO 9 can be used successfully in antibody constructs against HIV.
- the sequences ID NO 2, 3, 5, 6, 8 and 9 were designed based on the disclosure of Trkola et al 1996 (Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type I. J. Virol. 70:1100-1108), Kunert R., Rueker F., and Katinger H.
- polypeptide and/or an antibody construct is a polypeptide and/or antibody construct wherein at least one, preferred two constant domain of a light chain Q. comprises the amino acid sequence selected from the group comprising Seq. ID N0 10
- V L CDR3 comprises an amino acid sequence selected from the group comprising Seq. ID NO 36 (QQYSSYPLT), Seq. ID NO 37 (QQYNSYPLT), Seq. ID NO 38 (HQYSSYPLT), Seq. ID NO 39 (FQGSHVPYT) and/or Seq. ID NO 40 (QHFWSTPPT).
- V H CDR1 comprises Seq. ID N0 13
- V H CDR2 comprises Seq. ID NO 19
- V H CDR3 comprises Seq. ID NO 25
- at least one variable domain of a light chain comprises a V L CDR1 , a V L CDR2 and/or a V L CDR3, wherein V L CDR1 comprises Seq. ID NO 29, V L CDR2 comprises Seq. ID NO 33 and/or V L CDR3 comprises Seq. ID NO 37.
- V H CDR1 comprises Seq. ID N0
- V H CDR2 comprises Seq. ID NO 21
- V H CDR3 comprises Seq. ID NO 26
- at least one variable domain of a light chain comprises a V L CDR1 , a V L CDR2 and/or a V L CDR3, wherein V L CDR1 comprises Seq. ID NO 30, V L CDR2 comprises Seq. ID NO 34 and/or V L CDR3 comprises Seq. ID NO 39.
- Eimeria is a parasite responsible for the poultry disease coccidiosis. Medications are available for the parasite; however, they are expensive and drug resistance is common as well as possible drug residues in the meat once the animal is butchered. Symptoms of Emeria infection include bloody diarrhea due to intestinal epithelium dying off since a large number of oocysts and merozoites burst out of the cells. Necrotic tissue clogs the cecum causing the organ to die. There is no satisfying treatment of coccidosis so far, which is a major problem for the poultry industry. Therefore Eimeria is a preferred target for the antibody construct of the invention.
- polynucleotide comprising a nucleotide sequence which encodes a polypeptide and/or an antibody construct mentioned above.
- Polynucleotides generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DMA or modified RNA or DMA.
- polynucleotides as used herein refers to, among others, single- and double-stranded DMA, DNA that is a mixture of single- and double-stranded regions, single- and double- stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia.
- the invention in another preferred embodiment relates to a nucleotide construct comprising one of the polynucleotides mentioned above, wherein said polynucleotide is operably linked to a promoter that drives expression in a host cell.
- promoter refers to a DNA sequence which directs the transcription of a structural gene to produce mRNA.
- a promoter is located in the 5' region of a gene, proximal to the start codon of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.
- the introduced DNA Once the introduced DNA has been integrated into the plant cell genome, it is generally stable there and is maintained in the progeny of the originally transformed cell as well. Usually it contains a selection marker which allows the selection of transformed cells from those lacking the introduced DNA.
- This selection marker endows the transformed plant cells with resistance to a biocide or an antibiotic, such as kanamycin, G418, bleomycin, hygromycin, methotrexate, glyphosate, streptomycin, sulfonylurea, gentamycin or phosphinotricin and others.
- antibiotics such as kanamycin, G418, bleomycin, hygromycin, methotrexate, glyphosate, streptomycin, sulfonylurea, gentamycin or phosphinotricin and others.
- nutritive markers and screening markers such as GFP, green fluorescent protein are used as alternatives to antibiotics resistance markers.
- the promoter is preferably tissue specific, but it may also be development-specific.
- the promoter may e.g. be active in tissues that are used as fodder such as seed, leaf and fruit tissues.
- the most preferred promoters for plant expression are seed specific promoters.
- Useful promoters for seed specific expression are the USP promoter, preferably the long (Zakharov et al., 2004, J E ⁇ xp Bot 55: 1463-71 ) or the short USP promoter (Baumlein etal., 1991 , MoI Gen Genet 225: 459-67).
- leader sequences may also be introduced into the vector, e.g. in order to achieve secretion of the polypeptides of the present invention into the medium.
- the amino acid sequence "EEAYA” is a cleavage site at the C terminus of a leader sequence.
- the "KDEL” sequence at the C terminus of a polypeptide sequence is an endoplasmatic reticulum (ER) retention signal in plants.
- the antibody constructs are protected from degradation due to protease inhibitors, which are present in most seeds. Therefore long-term storage does not influence the activity or the amount of protein. It is another object of the invention to provide a composition comprising the antigen-binding polypeptide, the polynucleotide, the nucleic construct and/or the antibody construct of the present invention and an acceptable excipient, carrier, buffer and/or stabilizer.
- Antigen-binding polypeptides in the state of art may be degraded rapidly after oral application. Therefore special attention has to be given to the high acidity in the stomach as well as the presence of secretory proteases, particularly in the oral cavity and in the small intestine.
- the ex ⁇ pient carrier, buffer and/or stabilizer preferably comprises a protein source, such as BSA, milk powder and/or pea flour.
- the proteins may be added alone or as a protein mixture. Additionally or alternatively, the excipient, carrier, buffer and/or stabilizer may comprise methyl-cellulose.
- the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both.
- a syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compounds may be incorporated into sustained-release preparation and formulations.
- the pharmaceutical forms suitable for injectable use include sterile aqueous Solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable Solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
- aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous Solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure.
- carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifingal agents, isotonic and absorption delaying agents, buffers, carrier Solutions, suspensions, colloids, and the like.
- carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifingal agents, isotonic and absorption delaying agents, buffers, carrier Solutions, suspensions, colloids, and the like.
- the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- Example 3 Amino acid sequences of various polypeptide domains- Table 1 : Individual amino acid sequences of VH CDR1 , VH CDR2 and VH CDR3 of the Eimeria-binding polypeptides AA19, AA28, AB09, AB21 , AB28 and AD10.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a new antigen-binding polypeptide and/or an antibody construct with a cross-pairing antigen-binding structure, comprising cross-paired variable fragments of light and heavy chains, with additional constant light domains to facilitate enhanced dimerization. Furthermore the invention relates to a polynucleotide encoding said polypeptide, a vector comprising the polynucleotide and a prokaryotic or eukaryotic host cell comprising the polynucleotide, the vector and/or the polypeptide. The invention also relates to plants, parts thereof or microorganisms containing the polynucleotide, the vector and/or the polypeptide. Furthermore the invention relates to a composition comprising the polynucleotide, the polypeptide and/or the antibody construct and an acceptable excipient, carrier, buffer and/or stabilizer.
Description
Proteolytically stable antibody formats
Description
The present invention relates to a new antigen-binding polypeptide and/or an antibody construct with a cross-pairing antigen-binding structure, comprising cross-paired variable fragments of light and heavy chains, with additional constant light domains to facilitate enhanced dimerization. Furthermore the invention relates to a polynucleotide encoding said polypeptide, a vector comprising the polynucleotide and a prokaryotic or eukaryotic host cell comprising the polynucleotide, the vector and/or the polypeptide. The invention also relates to plants, parts thereof or microorganisms containing the polynucleotide, the vector and/or the polypeptide. Furthermore the invention relates to a composition comprising the polynucleotide, the polypeptide and/or the antibody construct and an acceptable excipient, carrier, buffer and/or stabilizer. Background
The immune system of vertebrates is a complex defence system that is responsible for distinguishing self from everything foreign to the organism, and for protecting the organism against infections and foreign substances. The immune system is divided into innate immune system, and acquired or adaptive immune system, each of which contains humoral and cellular components.
Humoral immunity refers to antibody production, and the accessory processes that accompany it. It also refers to the effector functions of antibodies, for example pathogen and/or toxin neutralization, classical complement activation, opsonin promotion of phagocytosis and pathogen elimination. Cell-mediated immunity involves the activation of macrophages, natural killer cells, antigen-specific cytotoxic T-Jymphocytes and the release of various cytokines in response to an antigen.
Despite all defence mechanisms, pathogens have evolved elaborate strategies to evade the immune response of an organism. Therefore there is a constant need for the development of new antigen-binding fragments. Antibodies, also known as immunoglobulins, are an indispensable component of the defence mechanism against potential pathogens. Antibodies are globular plasma proteins with a molecular weight of approximately 150 kDa. A full- length antibody as it exists naturally is an immunoglobulin molecule comprised of four peptide chains, two heavy (H) chains (about 50-70 kDa when full length) and two light (L) chains (about 25 kDa when full length) interconnected by disulfide bonds. The amino terminal portion of each chain includes a variable region primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
Light chains are classified as either kappa or lambda and are characterized by a particular constant region. Each light chain is comprised of an N-terminal light chain variable region (VL) and a light chain constant region (Q.) comprised of one domain. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD, and IgE, respectively and several of these may be further divided into subclasses (isotypes) e.g., IgGI , lgG2, lgG3, lgG4, IgAI and lgA2. Each heavy chain type is characterized by a particular constant region. Each heavy chain is comprised of an N-terminal heavy chain variable region (VH) and a heavy chain constant region (CH). The VH and CH regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions. The CDRs contain most of the residues which interact specifically with the antigen by forming a surface complementary to the antigen.
An antibody "Fab" fragment (fragment antigen binding) is the region of an antibody composed of a complete light chain linked to the N-terminal part of a heavy chain, consisting of the variable region (VH) and one constant domain (CNI ). The Fab fragment may be generated e.g. by papain hydrolysis of an antibody. The other part of an antibody is called "Fc" region (fragment crystallizable region) or "Fc" fragment. The Fc region is the tail region of an antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system.
One of the smallest molecules with an entire antigen binding site is the so-called single chain variable fragment (scFv). An ScFv is a fusion protein of the variable regions of the heavy and light chains of an immunoglobulin in a single polypeptide chain using a linker, essentially encompassing a truncated Fab fragment antigen binding site. Gene technology methods such as phage display allow the production of a recombinant single-chain variable fragment. Phage display is a standard technique for the presentation of distinct peptides, polypeptides or proteins on the surface of bacteriophages. It allows the identification of the exposed peptides, polypeptides or proteins via their binding properties. The technique is used for the establishment of libraries of peptide, polypeptide or protein variants such as different antibody fragments. For this, mammals such as mice are immunized against the antigen of interest and lymphocytes are isolated, e.g. from the spleen. Then, mRNA is isolated, and a cDNA library is generated by cloning the cDNA into a phage display vector. The phage display library generated in this way contains recombinant scFv antibody fragments. The random library is screened for protein-protein interactions, e.g. for their antigen binding specificities. Interacting clones of the library are enriched, and the phagemid DNA from individual clones can be isolated and sequenced. Using recombinant antibodies has significant advantages when compared to conventional antibodies and therefore their use is becoming more common. No animals are needed in the manufacturing procedure of the recombinant antibodies; in addition, the manufacturing time is relatively short compared with the conventional method. Moreover, the quality of the final product is higher that these of the non recombinant method. The construction of recombinant antibody fragments is based on methods of genetic engineering and the production can be carried out in vitro. Antibodies play an important role in clinical applications as well as diagnostic assays. Administration of antibodies is an attractive approach to establish protective immunity, employed in passive vaccination or in therapy. They are also used as vehicles that direct a linked moiety, e.g., an active agent or a toxin, to specific sites in the organism, where the antigens recognized by the antibodies expressed. Labelled antibodies can also be used for in vivo or in vitro diagnostics. There are two main methods of specific antibody use to defend an organism against certain pathogens; active and passive immunisation. Active immunization entails the introduction of an antigen into the body, which causes the body itself to generate immunity against the target. Active immunization is normally used for prophylaxis, like vaccination, but not for treatment of infections. Passive immunization is where pre-made elements, like antibodies, of the immune system are transferred to an organism. This method of immunization begins to work very quickly, but it is short lasting, because the antibodies are naturally broken down, and if there are no B cells to produce more antibodies, they will disappear.
Passive immunization can be used if there has been a recent outbreak of a particular disease or as an emergency treatment to poisons (for example, for tetanus). One of the drawbacks of passive immunization is the poor stability of most antibodies. Especially oral administration is not very effective, because the antibodies are denatured and degraded in the stomach due to proteolytic enzymes and the acidic environment. However, oral administration is the cheapest and most convenient method, particularly for the immunization of production animals.
It is an object of the present invention to provide novel antigen-binding polypeptides, particularly antibody fragments. These polypeptides preferably neutralize invasion, have a protective and/or curative effect and are superior to the antigen-binding polypeptides known in the state of art. More specifically, a preferred object of the present invention is to provide antibody constructs that can be used in passive immunization avoiding the limitations known in the state of art. A further object of the present invention is to provide polynucleotides and/or vectors encoding these polypeptides, prokaryotic or eukaryotic host cells comprising these polynucleotides, vectors and/or polypeptides, transgenic plants, parts thereof or microorganisms containing the polynucleotides, vectors and/or polypeptides of the present invention, as well as compositions comprising said antigen-binding polypeptides. These and further objectives are achieved by the subject-matter of the claims. Description
The present invention relates to a polypeptide, or a dimer of polypeptides or an antibody construct whereby each monomer polypeptide chain comprises a constant domain of an immunoglobulin light chain (Q.) and a variable domain
of an immunoglobulin light chain (VL) linked via a polypeptide linker to a variable domain of an immunoglobulin heavy chain (VH), wherein the VH domain of the first monomer associates with the VL domain of the second monomer to form a first antigen binding site; and the VH domain of the second monomer associates with the VL domain of the first monomer to form a second antigen binding site; whereby the polypeptide linker connecting the VH and VL domains of the same monomer is of such a length that the adjacent VH and VL domains of the same monomer are incapable of associating with each other to form an antigen binding site. The first aspect of the present invention provides an antibody construct, comprising
- two polypeptide monomers, each comprising
- one constant light domain, wherein the constant domains of both monomers are operatively connected, preferred via a disulfide bond,
- one variable light domain, wherein the variable light domain is connected to the constant light domain,
- one variable heavy domain, wherein the variable heavy domain is connected to the variable light domain via a linker, wherein said linker consists of 0-12 am ino acids, whereby the variable light domain of each monomer is operatively associated with the variable heavy domain of the other monomer, and the variable light domain of each monomer forms an antigen binding site with the variable heavy domain of the other monomer. That means the invention preferably provides a dimer of polypeptides, wherein each monomer comprises three domains and a linker (Figure 3). The three domains are a constant domain of a light chain, which can be either a kappa domain or a lambda domain, a variable domain of a light chain and a variable domain of a heavy chain. The constant domain of a light chain is connected to the variable domain of a light chain. And the variable domain of a light chain is connected to the variable domain of a heavy chain via a short linker, although it is also intended that the domains can be connected directly without a linker at all (linker of 0 amino acids). Both monomers form a dimer, preferred via a disulfide bond between both constant domains of the light chains.
One of the characteristics of the invention is that each of the two antigen-binding sites is formed by both monomers. The short linker of the invention does not allow an association of the variable domain of a light chain and a variable domain of a heavy chain of the same monomer, as is found for example in scFv. Therefore the variable domain of a light chain of one monomer forms an antigen binding site with the variable domain of a heavy chain of the other monomer.
This conformation is known as "cross-pairing", whereby a structure is formed commonly referred to as a "diabody". Diabodies represent dimers of scFv polypeptides whereby the adjacent VH and VL domains of the same monomer do not bind to one another, but instead the VH domain of one monomer binds to the VL domain of the other monomer, and vice versa.
Diabodies consisting of cross-paired small variable antibody fragments are known in the prior art (Holliger et al, 1993, Proc Natl Acad Sci, 15;90 (14):6444-8). The major benefit of cross-pairing variable regions is that dimerization provides two antigen-binding domains, and therefore provides the option of bivalent or bi-specific antigen binding, whereby the antibody fragment has two antigen binding regions that can be targeted to either the same or different antigen targets. However, such diabodies are only held together as dimers by non-covalent and relatively limited binding forces, resulting in sufficient dimer-binding for biological activity, although poor long term stability in storage or in vivo during treatment.
There is a clear need for modified diabodies capable of more efficient production, stronger dimer interactions and thus more favourable properties regarding biological activity and stability, both in storage and during treatment. ScFV fragments have been linked to IgGI Fc immunoglobulin domains in fusion proteins in an attempt to solve some of the known disadvantages of diabody constructs (Wu et al, 2001 , Protein Engineering, 14: 12, 1025-1033, and
Hayden et al, 1994, Therapeutic Immunology, 1 , 3-15). However, the addition of Fc fragments to single-chain antibodies has not necessarily provided a satisfactory solution to the problems of scFv antibody constructs. Such antibody constructs of the prior art demonstrate that scFv fragments fused to Fc fragments (scFv-Fc) represent an antibody format that results in only partial dimerization and only partial cross-pairing. After an analysis of the molecular forms of scFv-Fc antibody fragments, it appears that approximately 30-40% of the expressed monomers form dimers in vivo, whereas the remainder either remain as monomers or form multimers (Wu era/, Hayden era/). Furthermore, it appears that only a limited pool of the dimerized fragments exhibit cross-pairing, whereas the remainder of the dimers demonstrate pairing within the single monomer scFV polypeptide chains, as is seen in common scFv fragments. Therefore the production of scFv-Fc dimers is inefficient due to a low proportion of the expressed scFv-Fc monomer molecules actually forming the desired cross-paired dimer.
In addition to the poor production efficiency, Fc domains demonstrate another significant disadvantage in their susceptibility to proteolytic cleavage. The Fc domain is linked to the light chain fragment by a hinge region, a region which can be susceptible to protease attack, as seen in its susceptibility to Papain digestion, and therefore shows a greater risk of low stability. The heavy chain of an immunoglobulin molecule can contain approximately 450 amino acids, presenting a significant increase in size to the antibody fragment when an Fc-fragment is fused. The large size leads to multiple disadvantages.
EΞxpression of a scFv DNA construct fused to the heavy chain Fc region becomes more difficult to express in comparison to DNA open reading frames of shorter length. Production of recombinant antibodies commonly takes place through the expression of recombinant constructs encoding the antibody fragments in host cells. Larger antibody constructs are typically more lowly expressed, therefore limiting production capacity. Larger proteins are also more likely to be insoluble once expressed, particularly in bacterial expression systems, therefore requiring additional preparation work such as inclusion body preparation, extraction and re-solubilisation of the antibodies. Large antibodies are also clearly disadvantageous in the treatment of cancer, whereby smaller scFv antibody fragments have been shown to be better able in penetrating tumour mass and have shown improved localisation at tumour sites.
The large Fc region could also show a greater likelihood of protease degradation due to the presence of potential protease recognition sites. Large protein fragments are more likely to be targeted by proteases, thus reducing the effective half-life of the antibody in vivo. The inclusion of larger proteins in pharmaceutical compositions is also disadvantageous in comparison to small proteins. Solubility and stability issues are of huge importance in producing biological pharmaceutical preparations, thus the reduction of antibody size is likely to play a significant role in enhancing their application in pharmaceutical products. Furthermore, the presence of a heavy-chain Fc region could be more likely to induce a potentially dangerous immune reaction when administered in vivo, as the large Fc region is a more significant and accessible target for the host immune response and could lead to allergic reactions.
The present invention provides a novel antibody format comprising a dimer of polypeptides, with a cross-pairing antigen-binding structure, comprising cross-paired variable fragments of light and heavy chains, with additional constant light domains to facilitate enhanced dimerization. The format of the invention is surprisingly superior when compared to all formats disclosed in the prior art. The use of Q. domains solves many of the problems inherent in using Fc fragments, such as providing a smaller molecule that with improved expression levels and solubility, and additionally leads to surprising advantages such as enhanced binding strength and stability. It was until now unknown whether the Q. domain could solve the problems inherent in scFv or scFv-Fc fragments. Misfolding or poor stability can result in fractional populations of norvfunctional material and/or antibodies with the tendency to form large soluble aggregates which are potentially dangerous or immunogenic when used therapeutically. Other stability problems include impeded refolding, degradation, impaired avidity, aggregation, or loss of activity following storage. Unstable polypeptides suffer from many problems, including unsuitability for scale-up
production in bioreactors (e.g., because of low yield, significant levels of unwanted byproducts such as unassembled product, and/or aggregated material), difficulties in purification, and unsuitabilityfor pharmaceutical preparation and use (e.g., owing to significant levels of breakdown product, poor product quality, and/or unfavourable pharmacokinetic properties). Especially instability within the variable domains of antibodies, Fabs, Fvs, or scFvs may result in many of these problems. scFv constructs in particular have demonstrated problems with stability, solubility, expression, aggregation, breakdown products, and overall manufacturability. Additionally, incorporation of scFv molecules into otherwise stable recombinant antibody products often imparts these generally undesirable traits to the new recombinant design. Surprisingly the polypeptides of the present invention showed an enhanced stability in comparison with the antibody formats known in the prior art, especially diabodies or Fc-fused-diabody constructs. It was unexpected that the embodiments of the present invention would lead to antibody constructs stable enough to overcome the problems mentioned above.
It is known that the constant domains of a heavy chain are important for the good stability. Surprisingly the use of Q. domain dimerization has lead to polypeptides and/or antibody formats that are extremely stable without the presence of a constant domain of a heavy chain. The added stability is advantageous in many ways. A high stability is preferable because lower doses can be administered in pharmaceutical applications. Therefore a therapy comprising the antibody constructs of the present invention is less expensive compared to those of the prior art. There is no disclosure nor indication in the prior art that Q. domain addition could lead to enhanced stability, and thus overcome many of the disadvantages of the antibody constructs disclosed in the prior art. The constructs of the present invention lead to an increased performance and have an improved reliability and quality. The saving of time, material, work steps, costs and resources are also advantages of the present invention. The production of the polypeptides of the present invention is distinguished by a better yield and therefore price-reduction. Due to the shorter length of the Q. domain in comparison to the Fc-fused-diabodies, expression levels of the recombinant protein are higher and therefore more efficient and cost-effective Furthermore, it was surprising that a small linker consisting of 12 or less amino acids could be used to connect VL and VH. The use of a small linker prevents the assembling of VL and VH within the same chain. Thus each antigen binding site is formed by VL of one chain and VH of the other chain. Surprisingly these antigen binding sites lead to a higher affinity between antibody and antigen. Also this conformation is more stable compared to antibody constructs with longer linker sequences. Antibodies are targets for enzymatic cleavage, which is a major problem for antibody stability. It was surprising that the use of the short linker of the invention results in a conformation that protects the antibody construct from enzymatic cleavage, especially from proteases. It was not expected that antibody construct without a linker between VL and VH can be used to solve the technical problem. Therefore it was very surprising that the use of a construct without a linker showed good results in stability and specificity. Another surprising advantage of the present invention is the high expression levels of the polypeptides in various expression systems, especially in plants. It was unexpected that expression of the Q. domain-containing antibody constructs of the present invention would result in high expression and solubility and therefore high activity in plant expression systems. High expression levels in plants results in an enormous advantage in regards to providing the antibody to humans or animals in the plant form, without requiring additional separation, purification and preparation steps. For example, antibodies directed against bird, preferably chicken, pathogens could be expressed in plants and administered to chickens as fodder.
It is known in the prior art that Q. domains can be used to facilitate protein dimerization (Raats and Hof, 2004, European Journal of Cell Biology, 84, 517-521 ). However, there is no disclosure of Q. domains being applied in the context of a diabody or cross-pairing antibody structure. The disclosure of Raats and Hof relates to the application of Q_ domains to facilitate the dimerization of scFv fragments, whereby the scFv fragments exhibit interaction between the VH and VL domains within the individual monomers. The disclosure of Raats and Hof also reveals that, in the absence of cross-pairing scFv fragments, the Q. domains do not function optimally in achieving the desired dimerization, whereby additional Jun dimer domains are required to facilitate efficient formation a dimer pair.
In comparison to Fc dimerization, the use of Q. domains does not represent the exchange of one dimer domain for another, as Fc and Q. domains are clearly not equivalent. The properties of the Fc and Q. domains differ in many respects, as outlined above. Q. domains are small in comparison to Fc domains, they are relatively protease resistant and also demonstrate a surprisingly high efficiency in dimer formation, leading to a higher proportion of monomers forming dimers and thus enhancing the production efficiency.
Furthermore, the combination of cross-pairing scFv fragments with Q. domains, as is subject of the present invention, leads to surprising synergistic effects. The cross-pairing of the scFv fragments combined with the dimerization of the Q. domains lead to enhanced dimer formation and stability, more so than if either factor had been applied in isolation. The effective dimerization provided by the Q. domains, in concert with the cross-pairing scFv fragments, produces greater than additive effects.
In terms of the invention "antibody" or "antibody construct" refers to an intact antibody, or a fragment thereof. An antibody or antibody construct, is said to specifically bind an antigen when the dissociation constant is less than or equal to 1 μM, preferably less than or equal to 100 nM and most preferably less than or equal to 10 nM. Binding can be measured by methods known to those skilled in the art. Antibody constructs comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
"Polypeptides", as used herein, includes all polypeptides as described below. The basic structure of polypeptides is well known and has been described in innumerable textbooks and other publications in the art. In this context, the term is used herein to refer to any peptide or protein comprising amino acids joined to each other in a linear chain by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types.
It will be appreciated that polypeptides often contain amino acids other than the 20 amino acids at commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes such as glycosylation and other post-translational modifications, or by chemical modification techniques which are well known in the art. Common modifications include glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP- ribosylation, and these and others are described in most basic texts, such as, for instance, I. E. Creighton, Proteins- Structure and Molecular Properties, 2nd Ed., W. H. Freeman and Company, New York, 1993. Many detailed reviews are available on this subject, such as, for example, those provided by Wold, F., in Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, pp 1 -12, 1983; Seifter et al., Meth. Enzymol. 182: 626-646, 1990 and Rattan et al., Protein Synthesis: Posttranslational Modifications and Aging, Ann. N.Y. Acad. Sci. 663: 48-62, 1992.
It will be appreciated, as is well known, and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslational events, including natural processing events and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translational natural processes and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in E. coli, prior to proteolytic processing, almost invariably will be N-formylmethionine.
The modifications that occur in a polypeptide often will be a function of how it is made. For polypeptides made by expressing a cloned gene in a host, for instance, the nature and extent of the modifications in large part will be determined by the host cell posttranslational modification capacity and the modification signals present in the polypeptide amino acid sequence. For instance, as is well known, glycosylation often does not occur in bacterial hosts
such as E. cxili. Accordingly, when glycosylation is desired, a polypeptide should be expressed in a glycosylating host, generally a eukaryotic cell.
In general, as used herein, the term polypeptide encompasses all such modifications, particularly those that are present in polypeptides synthesized by expressing a polynucleotide in a host cell. In a preferred embodiment of the invention, the polypeptide is an antigen-binding peptide.
As used herein, the "antigen-binding" refers to that portion of a polypeptide and/or antibody which contains the amino acid residues that interact with an antigen and confer on the antibody its specificity and affinity for the antigen. The term "antigen-binding polypeptide" as used herein means a polypeptide or protein which, according to the invention, specifically binds to an antigen. The term "specific binding", "binding specificity, "as used herein means that the polypeptide of the present invention does not show any significant binding other molecules. Usually this binding is reversible and/or non-covalent. The term "heavy chain" or "light chain" as used herein means the conventional antibody polypeptide heavy chain (H) or light chain (L), respectively. The term "variable region" or "variable domain" as used herein means the conventional antibody variable region or variable domain or variable fragment (V or Fv) which confers antigen binding specificity. Variable regions employed in the invention may be derived from any germline or rearranged variable domain, or may be a synthetic variable domain based on consensus sequences of known variable domains. Usually the variable region of the heavy chain (VH) and the variable region of the light chain (VL) each comprise three complementarity determining regions CDR1 , CDR2 and CDR3. The term "single chain variable fragment" or "single-chain antibody" or "single-chain fragment1 ' as used herein means any polypeptide comprising the variable region of a heavy chain, the variable region of a light chain and a linking peptide between the variable region of the heavy and the light chain, resulting in a single chain Fv or "scFv". In terms of the invention a "domain" of a polypeptide or protein is a discrete part of an amino acid sequence that can be equated with a particular function. The new antigen-binding polypeptide and/or the antibody construct can be used in the treatment, prophylaxes, aftercare, follow-up treatment or diagnosis for all disease that can be treated with antibodies. Diseases in terms of the invention are viral infectious diseases, bacterial infectious diseases, parasitic infectious diseases, fungal infectious diseases, prion infectious diseases, tumor diseases and/or autoimmune diseases. All diseases that are caused by an infections agent or a pathogen can be treated and/or prevented with the polypeptides and/or antibody constructs of the invention.
As used herein, an "infectious agent" and "pathogen" denotes both microbes and parasites. A "microbe" includes viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganisms. A "parasite" denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which are susceptible to antibody-induced clearance or lytic or phagocytic destruction, such as malarial parasites, spirochetes, and the like. .Examples of infectious agents include, for example, a fungus, virus, parasite, bacterium, protozoan, or mycoplasm. For example the fungus may be from the species of Microsporum, Trichophyton, Epidemnophyton, Sporothrix schenckii, Cyiptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, or Candida albicans. For example the virus may be from the species of human immunodeficiency virus (HIV), herpes virus, cytomegalovirus, rabies virus, influenza virus, hepatitis B virus, SARS coronavirus, Sendai virus, feline leukemia virus, Reo virus, polio virus, human serum parvo-like virus, simian virus 40, respiratory syncytial virus, mouse mammary tumor virus, Varicella-Zoster virus, Dengue virus, rubella virus, measles virus, adenovirus, human T-cell leukemia viruses, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocytic choriomeningitis virus, wart virus and blue tongue virus. For example the bacterium may be, for example, Anthrax bacillus, Streptococcus agalactiae, Legionella pneumophila, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis
influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Mycobacterium leprae, Brucella abortus, and Tetanus toxin. For example the parasite may be a helminth or a malarial parasite.
For example the protozoan may be Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trypanosoma rangeli, Trypanosoma crυzi, Trypanosoma rhodesiensei, Trypanosoma brucei, Schistosoma mansoni, Schistosoma japanicum, Babesia bovis, Eimeria tenella, Onchocerca volvulus, Leishmania tropica, Trichinella spiralis, Onchocerca volvulus, Theileria parva, Taenia hydatigena, Taenia ovis, Taenia saginata, Echinococcus granulosus or Mesocestoides corti. The mycoplasma may be Mycoplasma arthritidis, Mycoplasma hyorhinis, Mycoplasma orale, Mycoplasma arginini, Acholeplasma laidlawii, Mycoplasma salivarum, and Mycoplasma pneumoniae. The use of the polypeptides and/or the antibody constructs of the invention is especially advantageous for AIDS, AIDS related complex, chickenpoxx, common cold, cytomegalovirus infection, Colorado tick fever -dengue fever, ebola hemorrhagic fever, hand, foot and mouth disease, hepatitis, herpes simplex, herpes zoster, HPV, influenza, lassa fever, measles, marburg hemorrhagic fever, infectious mononucleosis, mumps, norovirus, poliomyelitis, Progressive multifocal leukencephalopathy, rabies, rubella, smallpox, viral encephalitis, viral gastroenteritis, viral meningitis, viral pneumonia, West nile disease, yellow fever, anthrax, bacterial meningitis, botulism, brucellosis, campylobacteriosis, cat scratch disease, cholera, diphtheria, epidemic typhus, gonorrhea, impetigo, legionellosis, leprosy (hansen's disease), leptospirosis, listeriosis, lyme disease, melioidosis, rheumatic fever, MRSA infection, nocardiosis, pertussis (whooping cough), plague, pneumococcal pneumonia, psittacosis, Q fever, Rocky mountain spotted fever (RMSF), salmonellosis, scarlet fever, shigellosis, syphilis, tetanus, trachoma, tularemia, typhoid Fever, typhus, urinary tract infections, african trypanosomiasis, amebiasis, ascariasis, babesiosis, chagas disease, clonorchiasis, cryptosporidiosis, cysticercosis, diphyllobothriasis, dracunculiasis, echinococcosis, enterobiasis, fascioliasis, fasciolopsiasis, filariasis, free-Jiving amebic infection, giardiasis, gnathostomiasis, hymenolepiasis, isosporiasis, kala-azar, leishmaniasis, malaria, metagonimiasis, myiasis, onchocerciasis, pediculosis, pinworm Infection, Severe acute respiratory syndrome (SARS), scabies, schistosomiasis, taeniasis, toxocariasis, toxoplasmosis, trichinellosis, trichinosis, trichuriasis, trichomoniasis, tuberculosis, trypanosomiasis, aspergillosis, blastomycosis, candidiasis, coccidiosis. coccidioidomycosis, cryptococcosis, histoplasmosis, tinea pedis, transmissible spongiform encephalopathy, bovine spongiform encephalopathy, creutzfeldkJakob disease, alpers Syndrome, acute disseminated encephalomyelitis, addison's disease, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, coeliac disease, chagas disease, chronic obstructive pulmonary disease, dermatomyositis, diabetes mellitus type 1 , endometriosis, goodpasture's syndrome, graves' disease, guillain-barre syndrome, hashimoto's disease, hydradenitis suppurativa, idiopathic thrombocytopenic purpura, interstitial cystitis, lupus erythematosus, morphea, multiple sclerosis, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, schizophrenia, scleroderma, Sjogren's syndrome, temporal arteritis, vasculitis, vitiligo, Wegener's granulomatosis, leukemia, adrenocortical carcinoma, basal cell carcinoma, bile duct cancer, extrahepatic, bladder cancer, bone cancer, osteosarcoma, brain stem glioma, brain tumor, breast cancer, bronchial adenomas, burkitt lymphoma, carcinoma, colon cancer , esophageal cancer, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor (GIST), glioma, hepatocellular cancer, hodgkin lymphoma, renal cell cancer, liver cancer, lung cancer, lymphomas, melanoma, mesothelioma, neuroblastoma, non-hodgkin lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, salivary gland cancer, testicular cancer and/or urethral cancer.
The increasing number of antibiotic-resistant bacteria emphasizes the need to find alternatives. Surprisingly, the antigen-binding polypeptides and/or antibody constructs can also be used as a complementary treatment against pathogens that are difficult to treat with traditional antibiotics. Surprisingly the antibody construct and/or the antigen-binding polypeptide of the invention can also be advantageously used in all in vitro diagnostic methods, where their use minimizes cross-reactivity and false positive and negative results.
In terms of the invention, the antigen-binding polypeptide and/or the antibody construct can be constructed in a way they are able to bind a certain antigen. A person skilled in the art knows how to adapt the CDR regions of the polypeptide and/or the antibody construct of the invention in a way in binds to a given antigen. Any antigen-binding polypeptide with the structure explained above is an antibody construct of the invention, regardless of the antigen specificity.
While the invention has been described in terms of preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the claims of the invention, including equivalents thereof. Therefore, as will be apparent to those skilled in the art to which the invention is addressed, the present invention may be embodied in forms other than those specifically disclosed without departing from the spirit or essential characteristics of the invention. The particular embodiments of the present invention as described are therefore to be considered in all respects as illustrative and not restrictive. The scope of the present invention is as set forth in the appended claims rather than being limited to the examples contained in the foregoing description. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the claims of the invention define the scope of the invention and that the method and apparatus within the scope of these claims and their equivalents be covered thereby. Those skilled in the art will therefore understand all those molecules as equivalent which he may apply without this having an effect on the solution of the problem of the invention. They know that the claimed sequences must not be modified by changes, substitutions or deletions in a way that they cannot be used for solving the problem of the invention. A second aspect of the present invention relates to a polypeptide, comprising
- two constant domains of a light chain and
- two single chain variable fragments, comprising - a variable domain of a light chain,
- a variable domain of a heavy chain and
- a linker, wherein said linker consists of 0-12 amino acids, and is interposed between the variable light domain and the variable heavy domain, and each variable domain of a light chain forms an antigen binding site with the variable domain of a heavy chain of the other single chain variable fragment, wherein each single chain variable fragment is associated with a constant domain of a light chain. A third aspect of the present invention relates to an antibody construct, comprising
- two constant domains of a light chain, wherein the two constant domains of a light chain are operatively connected, preferred via a disulfide bond,
- two variable domains of a light chain, wherein each variable domain of a light chain is associated with a constant domain of a light chain,
- two variable domains of a heavy chain, wherein each variable domain of a heavy chain is connected to a variable domain of a light chain via a linker, wherein said linker consists of 0-12 amino acids. A fourth aspect of the present invention relates to an antibody construct, comprising
- two monomers, each comprising
- one constant light domain, wherein the constant domains of both chains are operatively connected, preferred via a disulfide bond,
- one variable light domain, wherein the variable light domain is associated with the constant domain,
- one variable heavy domain, wherein the variable heavy domain is connected to the variable light domain via a linker, wherein said linker consists of 0-12 amino acids, whereby the variable light domain of each chain is operatively associated with the variable heavy domain of the other chain.
In an especially preferred embodiment the present invention provides a polypeptide and/or antibody construct that exhibits all the elements and features of the four aspects of the invention. Such an embodiment is especially effective in providing a solution to the task of the present invention. In another preferred embodiment the present invention relates to the polypeptide and/or antibody construct, wherein both constant domains of a light chain are kappa domains. Surprisingly the use of kappa chains resulted in high bioactivity and thus greater efficiency. The use of kappa chains is also advantageous because the transient expression of these antibody constructs is surprisingly high. Such constructs are known as Di-kappa-bodies. Also preferred is the polypeptide and/or the antibody construct, wherein both constant domains of a light chain are lambda domains. The use of lambda chains resulted in a surprisingly high activity in vifro and in vivo. A high activity is especially advantageous for therapeutical application because a lower dose can be used which prevents side effects. Also preferred is the polypeptide and/or the antibody construct of the invention, wherein the constant domains are connected, preferred covalently, especially via a disulfide bridge. Dimers that are formed by non-covalent association often dissociate; the invention solves this problem by introducing a disulfide bond, preferably between Q. domain fragments. Analyses of molecular forms proved that the polypeptides and/or antibodies of the present invention do not dissociate and are therefore dimeπ'c.
Surprisingly the disulfide bridge leads to a much higher stability, especially proteolytic stability, of the fragment. The antigen-binding polypeptide and/or the antibody construct bearing a disulfide bridge are more resistant to for example enzymatic cleavage. This leads to a higher half-life in an organism, which results in a higher efficacy. Poor stability can affect the ability of an antibody or antibody domain to fold property when expressed in various cellular systems, e.g., in bacterial or mammalian expression systems.
Also preferred is the polypeptide and/or the antibody construct of the invention, wherein the constant domains are connected via hydrophobic interaction. Hydrophobic interaction can be superior to covalent associations under certain circumstances. A person skilled in the art knows that there are several ways to connect two chains of a polypeptide. Disulfide bridges and hydrophobic interactions are preferred embodiments of the invention, however it is understood that any kind of connection, covalent or non- covalent, known in the state of art can be used to connect the polypeptide of the invention. A skilled person knows that which connection or association is suited best for a certain condition. Another preferred embodiment of the invention is the polypeptide and/or the antibody construct, wherein said linker is not susceptible to protease cleavage. In the prior art the linkers in antibody constructs are often a target for protease cleavage. The special linkers of the invention are resistant to enzymatic cleavage, especially protease cleavage. Especially preferred is a linker, comprising the amino acid sequence of Seq. ID NO 41 (GGSGGS). The use of this linker resulted in an extremely high stability of the antibody construct. The antibody constructs of the invention are more stable and therefore superior compared to antibodies in the state of art.
As is well-known to those skilled in the art, some amino acids have analogous physicochemical properties so that these amino acids advantageously can be replaced by each other. For example, these include the group of nonpolar (hydrophobic) amino acids (a) glycine, alanine, valine, leucine and/or isoleucine; or the hydroxy amino acids (b) serine, threonine and/or tyrosine, the amides of amino dicarboxylic acids (c) asparagine and glutamine, the amino dicarboxylic acids (d) aspartic acid and glutamic acid; the basic amino acids (e) lysine, arginine and/or ornithine as well as the group of aromatic amino acids (f) phenylalanine, tyrosine and/or tryptophan. Another aspect is the replacement of amino acids by structural similar amino acids. For example this is the case in the group with a β-functional group (g) cysteine, methionine, serine, α- aminobutyric acid and selenocysteine as well as the turn-inducing group (h) praline, 1 -aminc-2- carboxy cyclohexane, pipecolic acid and an ortho-aminobenzoic acid. Amino acids within one and the same group (a- h) can be replaced with one another. In all cases, peptide sequences will have a sufficient homology to be an
analogous to an amino acid sequence of the peptides of the invention. Furthermore, the amino acids can be replaced by modified amino acids or specific enantiomers. Further modifications are possible in accordance with the teaching of WO 99/62933 or WO 02/38592. It is obviously known to a person skilled in the art that it is possible to provide functionally analogous means for the peptides and nucleic acids of the invention. In the meaning of the invention, "functionally analogous means" are means which are functionally equivalent or equivalent to the peptides and nucleic acids of the invention. In order to check whether a sequence is functionally equivalent (= equivalent) to the peptides or nucleic acids of the invention, one must check whether the functionally analogous/equivalent sequence of the peptide or of the nucleic acid produces essentially the same function in essentially the same way with essentially the same outcome. That is, the outcome produced with the peptides or nucleic acids of the invention may also be produced with the functionally analogous/equivalent means. A person skilled in the art can therefore easily and quickly verify whether a functionally analogous/equivalent sequence provided by them is covered by the invention. The functionally analogous sequence is covered by the invention if it may be used for solving the problem of the invention and if the solving of the problem of the invention can be earned out in essentially the same way as is claimed by the invention. In another advantageous embodiment of the invention the amino acid molecule has at least 60%, preferably 70%, more preferably 80%, especially preferably 90% homology to the amino acid molecule of Seq. ID NO 41.
Also preferred is the use of the linker of the invention for the preparation of an antibody construct. Surprisingly this linker can not only be used in the antibody constructs of the invention but also in other antibody constructs known in the prior art. It was very surprising that by the use of the linker in known antibody constructs, these constructs become more stable, more specific and therefore more effective. In another preferred embodiment the invention relates to the polypeptide and/or the antibody construct, wherein said polypeptide and/or antibody construct is monospecific.
In another preferred embodiment the present invention relates to the polypeptide and/or the antibody construct, wherein said polypeptide and/or an antibody construct is bispecific. Preferred is a bispecific protein dimer, comprising one monomer, wherein said VH domain of specificity A is linked to a light chain of specificity B, and the second monomer, wherein said VH domain of specificity B is linked to a light chain of specificity A.
Whether a monospecific or a bispecific antibody construct is suited for any given application depends on the target. One benefit of the bispecific antibody construct is that it is possible for such an antibody to simultaneously bind two different antigens, for example a bispecific antibody can bind to a cytotoxic cell and a target cell at the same time. Monospecific antibodies bind to the same antigen sequence with both antigen binding sites; therefore they can neutralize or eliminate the antigen in a very effective way. The use of monospecific antibodies is also preferred in diagnostics.
Also preferred is the polypeptide and/or the antibody construct wherein said linker is selected from the group consisting of a GS-linker, a yoHinker and/or a linker with the amino acid sequence GGSGGS. There is no proteolytic cleavage site in the GGSGGS linker, which helps to prevent enzymatic cleavage. The GGSGGS linker is relatively inflexible, which is advantageous for the conformation of the polypeptide and/or antibody construct of the invention. It is understood, that a person skilled in the art knows that certain amino acids can be replaced by others. Another preferred embodiment of the invention is the polypeptide and/or the antibody construct, wherein the polypeptide and/or an antibody construct is a non-immunoglobulin polypeptide. A non-immunoglobulin polypeptide does not have an Fc region and is therefore much smaller compared to a full length antibody. Antibodies without an Fc region are superior for the use in diagnostics, because they do not interact with Fc receptors and therefore cause a decreased background staining. Additionally the lower molecular mass compared to a full-length antibody is associated with increased expression rates.
Another preferred embodiment of the invention is the polypeptide and/or the antibody construct, comprising the amino acid sequence selected from the group comprising Seq. ID N0 1
(QVQLQQSGPELVKPGASVKMSCKASGYTFTVYIIHWLKQKPGQGLEWIGYINPYNDGTKYNEKFRGKATLTSDKS SSTAYMELSSLTSEDSANΛΎCARFYYGSSSVFDYWGQGTTLTVSSGGSGGSDVVMTQTQKFMSTSVGDRVSVT
CKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPL TFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS TΥSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEX; wherein X is a deletion or C), Seq. ID NO 2 (EVQLVESGGGL\Λ<AGGSLILSCGVSNFRISAI-ΓΓMNWVRRVPGGGLE\ΛΛ/ASISTSSTYRDYADAVKGRFTVSRDD LEDFVYLQMHKMRVEDTAIYYCAF^GSDRLSDNDPFDAWGPGTΛΛM/SPGGSGGSDWMTQSPSTLSASVGDTI TITCRASQSIF-TWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISGLQFDDFAPMCQI-IYAGYS ATFGQGTRVEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC) and/or Seq. ID NO 3
CTLKESGPPLVKPTQTLTLTCSFSGFSLSDFGVGVGWIRQPPGKALEWLAIIYSDDDKRYSPSLNTRLTΓTKDTSKNQ V\Λ.^/^^RVSPVDTATYFCAHRRGPTTLFGVPIARGPV^^MD\ΛΛ/GQGITVTISSTGGSGGSDMRVPAQLLGLLLLW LPGARCALQLTQSPSSLSASVGDRMTCRASQG VTSALAWYRQKPGSPPQLLIYDASSLESGVPSRFSGSGSGTE FTLTISTLRPEDFATYYCQQLHFYPHTFGGGTRVDVRRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC).
Antibody constaicts comprising sequence ID N0 1 showed especially good results in experiments with Eimeria. A dimer consisting of two chains, each comprising Seq. ID N0 1 resulted in a high activity against the Eimeria antigen in vitro.
Antibody constructs comprising sequence ID NO 2 and 3 exhibited a good activity against HIV. The expression levels of dimers consisting of two chains, each comprising Seq. ID NO 2 and/or 3 were surprisingly high. Additionally antibody constructs comprising Seq. ID NO 3 were extremely stable, even under reducing conditions most of the polypeptides were present in the dimeric form.
Another preferred embodiment of the invention is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain VH comprises the amino acid sequence selected from the group comprising Seq. ID NO 4
(QVQLQQSGPELNΛ^GASVKMSCKASGYTFTVYIIHWLKQKPGQGLEWIGYINPYNDGTKYNEKFRGKATLTSDKS
SSTAYMELSSLTSEDSAVYYCARFYYGSSSVFDYWGQGTTLTVSS),
Seq. ID NO 5
(EVQLN^SGGGLNΛKAGGSLILSCGVSNFRISAHTMNWVRRVPGGGLEWVASISTSSTYRDYADAVKGRFTVSRDD LEDFVYLQMHKMRVEDTAIYYCARKGSDRLSDNDPFDAWGPGTWTVSP) and/or Seq. ID NO 6
(TLKESGPPLVKPTQTLTLTCSFSGFSLSDFGVGVGWIRQPPGKALEWLAIIYSDDDKRYSPSLNTRLTΓTKDTSKNQ NΛ^VΛ^RVSPVDTATYFCAHRRGPTTLFGVPIARGPVNAMDVWGQGΓTVTISST).
The use of Seq. ID NO 4 in an antibody construct led to a high specificity against the Eimeria antigen, whereas the use of Seq. ID NO 5 and 6 was superior for the binding of HIV.
Also preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a light chain VL comprises the amino acid sequence selected from the group comprising Seq. ID NO 7
(DVVIvTTQTQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTL
TISNVQSEDLAEYFCQQYNSYPLTFGAGTKLELK), Seq. ID NO 8
(DVVMrQSPSTLSASVGDTITrTCRASQSIETWLAWYQQKPGKAPKLLIYKASTLKTGVPSRFSGSGSGTEFTLTISG
LQFDDFATYHCQHYAGYSATFGQGTRVEIK) and/or Seq. ID NO 9
(DMRVPAQLLGLLLLWLPGARCALQLTQSPSSLSASVGDRITΓTCRASQGVTSALAWYRQKPGSPPQLLIYDASSLE SGVPSRFSGSGSGTEFTLTISTLRPEDFATYYCQQLHFYPHTFGGGTRVDVR).
The VL domain comprising Seq. ID NO 7 was advantageous in antibody constructs directed against Eimeria. VL domains comprising Seq. ID NO 8 and/or Seq. ID NO 9 can be used successfully in antibody constructs against HIV.
The sequences ID NO 2, 3, 5, 6, 8 and 9 were designed based on the disclosure of Trkola et al 1996 (Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type I. J. Virol. 70:1100-1108), Kunert R., Rueker F., and Katinger H. 1998 (Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventjonal D Segments in the Human Monoclonal Antibodies 2G12 and 2F5. Aids Resesearch and human retroviruses. Vo1 14(13):1115-1128) and Purtschner et al 1994 (A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus typ I. AIDS RESearch and HUMAN RETROVIRUSES VoI 10:1651-1658)
In another preferred embodiment of the invention the polypeptide and/or an antibody construct, is a polypeptide and/or antibody construct wherein at least one, preferred two constant domain of a light chain Q. comprises the amino acid sequence selected from the group comprising Seq. ID N0 10
(RTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREΞAKVQWKVDNALQSGNSQESVTEQDSKDSTΎSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC).
Surprisingly Q. domains with the amino acid sequence of Seq. ID N0 10 showed very good results. The stability of antibody constructs with two CL domains comprising Seq. ID N0 10 was superior to other constructs. Advantageous is also the high binding affinity of these construct to various antigens, for example antigens associated with Eimeria, HIV, SARS or Tuberculosis.
Another preferred embodiment is the polypeptide and/or an antibody construct wherein at least one variable domain of a heavy chain VH comprises a VHCDR1 , wherein VHCDR1 comprises an amino acid sequence selected from the group comprising Seq. ID N0 11 (DHAIH), Seq. ID N0 12 (VYIIH), Seq. ID N0 13 (SYAMS), Seq. ID N0 14 (NFWMH), Seq. ID NO 15 (NFWIH) and/or Seq. ID NO 16 (DTYIH).
Also preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR2, wherein VH CDR2 comprises an amino acid sequence selected from the group comprising Seq. ID NO 17 (YFSPGNNDIKYNEKFKG), Seq. ID NO 18 (YINPYNDGTKYNEKFRG), Seq. ID NO 19 (SISSGGSTYYPDSVKG), Seq. ID NO 20 (EINPSNGDTNYNEKFKR), Seq. ID NO 21 (EINPSNGDTKYNEKFRR) and/or Seq. ID NO 22 (RIDPANGNTKYDPKFQG).
Also preferred is the polypeptide and/or an antibody construct wherein at least one variable domain of a heavy chain comprises a VH CDR3, wherein VH CDR3 comprises an amino acid sequence selected from the group comprising Seq. ID NO 23 (WPGAMDY), Seq. ID NO 24 (FYYGSSSVFDY), Seq. ID NO 25 (NYGSYWGDSYFFDY), Seq. ID NO 26 (RGWLHFWYFDV) and/or Seq. ID NO 27 (SLGDYFAMNY). In another preferred embodiment the invention relates to the polypeptide and/or an antibody construct, wherein at least one variable domain of a light chain comprises a VL CDR1 , wherein VL CDR1 comprises an amino acid sequence selected from the group comprising Seq. ID NO 28 (KASQDVGTAVA), Seq. ID NO 29 (KASQNVGTNVA), Seq. ID NO 30 (RSSQSLENSNGN TYLN) and/or Seq. ID NO 31 (RASGNIHNYLA). Also preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a light chain comprises a VL CDR2, wherein VL CDR2 comprises an amino acid sequence selected from the group comprising Seq. ID NO 32 (WASTRHT), Seq. ID NO 33 (SASYRYS), Seq. ID NO 34 (KVSNRFS), and/or Seq. ID NO 35 (NAKTLAD).
Also preferred is the polypeptide and/or an antibody construct wherein at least one variable domain of a light chain comprises a VL CDR3, wherein VL CDR3 comprises an amino acid sequence selected from the group comprising Seq. ID NO 36 (QQYSSYPLT), Seq. ID NO 37 (QQYNSYPLT), Seq. ID NO 38 (HQYSSYPLT), Seq. ID NO 39 (FQGSHVPYT) and/or Seq. ID NO 40 (QHFWSTPPT).
Preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR1 , a VH CDR2 and/or a VH CDR3, wherein VH CDR1 comprises Seq. ID N0 11 , VH CDR2 comprises Seq. ID N0 17 and/or VH CDR3 comprises Seq. ID NO 23 and wherein at least one variable domain of a light chain comprises a VL CDR1 , a VL CDR2 and/or a VL CDR3, wherein VL CDR1 comprises Seq. ID NO 28, VL CDR2 comprises Seq. ID NO 32 and/or VL CDR3 comprises Seq. ID NO 36.
Preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR1 , a VH CDR2 and/or a VH CDR3, wherein VH CDR1 comprises Seq. ID N0 12, VH CDR2 comprises Seq. ID N0 18 and/or VH CDR3 comprises Seq. ID NO 24 and wherein at least one variable domain of a light chain comprises a VL CDR1 , a VL CDR2 and/or a VL CDR3, wherein VL CDR1 comprises Seq. ID NO 29, VL CDR2 comprises Seq. ID NO 33 and/or VL CDR3 comprises Seq. ID NO 37.
Preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR1 , a VH CDR2 and/or a VH CDR3, wherein VH CDR1 comprises Seq. ID N0 13, VH CDR2 comprises Seq. ID NO 19 and/or VH CDR3 comprises Seq. ID NO 25 and wherein at least one variable domain of a light chain comprises a VL CDR1 , a VL CDR2 and/or a VL CDR3, wherein VL CDR1 comprises Seq. ID NO 29, VL CDR2 comprises Seq. ID NO 33 and/or VL CDR3 comprises Seq. ID NO 37.
Preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR1 , a VH CDR2 and/or a VH CDR3, wherein VH CDR1 comprises Seq. ID N0 14, VH CDR2 comprises Seq. ID NO 20 and/or VH CDR3 comprises Seq. ID NO 26 and wherein at least one variable domain of a light chain comprises a VL CDR1 , a VL CDR2 and/or a VL CDR3, wherein VL CDR1 comprises Seq. ID NO 28, VL CDR2 comprises Seq. ID NO 32 and/or VL CDR3 comprises Seq. ID NO 38.
Preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR1 , a VH CDR2 and/or a VH CDR3, wherein VH CDR1 comprises Seq. ID N0 15, VH CDR2 comprises Seq. ID NO 21 and/or VH CDR3 comprises Seq. ID NO 26 and wherein at least one variable domain of a light chain comprises a VL CDR1 , a VL CDR2 and/or a VL CDR3, wherein VL CDR1 comprises Seq. ID NO 30, VL CDR2 comprises Seq. ID NO 34 and/or VL CDR3 comprises Seq. ID NO 39.
Preferred is the polypeptide and/or an antibody construct, wherein at least one variable domain of a heavy chain comprises a VH CDR1 , a VH CDR2 and/or a VH CDR3, wherein VH CDR1 comprises Seq. ID N0 16, VH CDR2 comprises Seq. ID NO 22 and/or VH CDR3 comprises Seq. ID NO 27 and wherein at least one variable domain of a light chain comprises a VL CDR1 , a VL CDR2 and/or a VL CDR3, wherein VL CDR1 comprises Seq. ID NO 31 , VL CDR2 comprises Seq. ID NO 35 and/or VL CDR3 comprises Seq. ID NO 40.
In another advantageous embodiment of the invention the polypeptides comprises sequence, wherein said sequence has at least 60%, preferably 70%, more preferably 80%, especially preferably 90% homology to the amino acid molecule of any of the Seq. ID N0 1 to Seq. ID NO 40. In another preferred embodiment the invention relates to the polypeptide and/or an antibody construct, wherein the polypeptide binds to Eimeria, preferred Eimeria tenella, HIV, Hepatitis B, SARS coronavirus, Mycobacterium tuberculosis and/or Mycobacterium leprae.
Also preferred is the polypeptide and/or the antibody construct which neutralizes or ameliorates the pathogenic effects of a pathogen, preferred Eimeria, Eimeria tenella, HIV, Hepatitis B, SARS coronavirus, Mycobacterium tuberculosis and/or Mycobacterium leprae. Also preferred is the polypeptide and/or the antibody construct which interferes with invasion, establishment or propagation of Eimeria species in birds, preferred poultry, more preferred chicken.
Eimeria is a parasite responsible for the poultry disease coccidiosis. Medications are available for the parasite; however, they are expensive and drug resistance is common as well as possible drug residues in the meat once the animal is butchered. Symptoms of Emeria infection include bloody diarrhea due to intestinal epithelium dying off since a large number of oocysts and merozoites burst out of the cells. Necrotic tissue clogs the cecum causing the organ to die. There is no satisfying treatment of coccidosis so far, which is a major problem for the poultry industry. Therefore Eimeria is a preferred target for the antibody construct of the invention.
Another preferred embodiment of the invention is a polynucleotide comprising a nucleotide sequence which encodes a polypeptide and/or an antibody construct mentioned above. Polynucleotides) generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DMA or modified RNA or DMA. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DMA, DNA that is a mixture of single- and double-stranded regions, single- and double-
stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
As used herein, the term "polynucleotide" includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritium-labelled bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia.
In another preferred embodiment the invention relates to a nucleotide construct comprising one of the polynucleotides mentioned above, wherein said polynucleotide is operably linked to a promoter that drives expression in a host cell. The term "promoter" refers to a DNA sequence which directs the transcription of a structural gene to produce mRNA. Typically, a promoter is located in the 5' region of a gene, proximal to the start codon of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Another preferred embodiment of the invention relates to vector comprising one of the mentioned polynucleotide or the nucleotide construct. The term "vector" includes a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked including, but not limited to, plasmids and viral vectors. Certain vectors are capable of autonomous replication in a host cell into which they are introduced while other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby, are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Especially preferred is a phage display vector, a bacterial expression vector, a yeast expression vector, a fungus expression vector, an algae expression vector or a plant expression vector.
In order to prepare the introduction of foreign genes into higher plants a variety of vectors are available which contain replicating signals for E coli and a marker gene for selecting transformed bacterial cells. Examples for such vectors are pBR322, pUC series, M13mp series, pACYC184, pBlueSfi and the like. The desired sequence may be introduced into the vector at a suitable restriction site. The resulting plasmid is then used for the transconstruction of E coli cells. Transformed E. coli cells are cultivated in a suitable medium and then harvested and lysed, and the plasmid is recovered. In order to characterize the produced plasmid DNA in general, restriction analysis, gel electrophoresis and further biochemical and molecular biological methods are used. After each manipulation step the plasmid DNA may be cleaved and the obtained DNA fragments may be linked to other DNA sequences. Several known techniques are available for introducing DNA into a plant host cell, and the person skilled in the art will not have any difficulties in selecting a suitable method. These techniques comprise the transconstruction of plant cells with T-DNA by use of Agrobactehum tumefaciens or Agrobacterium rhizogenes as the transform ing agent, the fusion of protoplasts, the direct gene transfer of isolated DNA into protoplasts, the electroporation of DNA, the introduction of DNA by means of the biolistic method as well as further possibilities. For injection and electroporation of DNA into plant cells, no specific requirements for the plasmids are necessary per se. The same is true for direct gene transfer. Plain plasmids such as pUC and pBlueScript derivatives may be used. The presence of a selectable marker gene is necessary if entire plants are to be regenerated from such transformed cells. The person skilled in the art is familiar with these gene selection markers and will not have any problems in selecting a suitable one. Further DNA sequences may be required depending on the introduction method for desired genes into the plant cell. If, for example, the Ti or Ri plasmid is used for the transconstruction of the plant cell, at least the right border, however
more often both the right and the left border of the T-ONA in the Ti or Ri plasmid, has to be linked as flanking region to the genes to be introduced.
If agrobacteria are used for transconstruction, the DNA to be introduced has to be cloned into special plasmids, either into an intermediate or into a binary vector. Intermediate vectors may be integrated into the Ti or Ri plasmid of the agrobacteria by homologous recombination via sequences which are homologous to sequences in the T-DNA. This also contains the w region which is required for T-DNA transfer. Intermediate vectors are not able to replicate in agrobacteria. With the aid of a helper plasmid the intermediate vector may be transferred to Agrobacterium tumefaciens via conjugation. Binary vectors are able to replicate in £ coli as well as in agrobacteria. They contain a selection marker gene, and a linker or polylinker framed by the right and left T-DNA border region. They may be transformed directly into agrobacteria. The agrobacterial host cell should contain a plasmid with a vir region. The vir region is required for the transfer of the T-DNA into the plant cell. Additional T-DNA may be present. Such a transformed agrobacterial cell is used for the transconstruction of plant cells.
The use of T-DNA for the transconstruction of plant cells has been studied intensively, and has been sufficiently described in generally known reviews and plant transconstruction manuals. For transfer of the DNA into the plant cell, plant explants may be cultivated for this purpose together with Agrobacterium tumefaciens at Agrobacterium rhizogenes. From the infected plant material (e.g. leaf pieces, stem segments, roots, but also protoplasts or suspension-cultivated plant cells) whole plants may be regenerated in a suitable medium which may contain antibiotics or biocides for selection of transformed cells. Regeneration of plants may take place according to conventional regeneration methods by use of known growth media. The resulting plants may be analyzed for the presence of the introduced DNA. Other possibilities for the introduction of foreign DNA by use of biolistic methods or protoplast transconstruction are well known and as have been described extensively.
Once the introduced DNA has been integrated into the plant cell genome, it is generally stable there and is maintained in the progeny of the originally transformed cell as well. Usually it contains a selection marker which allows the selection of transformed cells from those lacking the introduced DNA. This selection marker endows the transformed plant cells with resistance to a biocide or an antibiotic, such as kanamycin, G418, bleomycin, hygromycin, methotrexate, glyphosate, streptomycin, sulfonylurea, gentamycin or phosphinotricin and others. But also nutritive markers and screening markers (such as GFP, green fluorescent protein) are used as alternatives to antibiotics resistance markers. It is also possible to perform this selection procedure without any selection marker, however, this requires a quite high screening expenditure. The resulting plants may be cultivated normally, and may be crossbred with plants having the same transformed hereditary disposition or other predispositions. The resulting hybrids will have the pertinent phenotype characteristics. Seeds may be obtained from the plant cells. Two or more generations should be generated to ensure that the phenotypic feature is stably maintained and inherited. Additionally, seeds should be harvested to verify the maintenance of the respective phenotype or other features. In a preferred embodiment, the vector comprising the polynucleotide which encodes the antigen-binding polypeptide of the present invention, preferrd the antibody fragment or a derivative thereof, which specifically binds to Eimeria, contains specific regulatory elements, either constitutive or inducible either by biotic or abiotic stimuli, especially promoters, specific for the expression of the cloned construct in the prokaryotic or eukaryotic host cell, e.g. in bacteria, yeast or plant cells. For the expression of the polypeptides of the present invention in a plant cell or a microorganism cell, in principle any promoter can be considered which is active in the respective host cell. The promoter may be homologous or heterologous to the cell to be transformed.
For plant expression, the promoter is preferably tissue specific, but it may also be development-specific. The promoter may e.g. be active in tissues that are used as fodder such as seed, leaf and fruit tissues. The most preferred promoters for plant expression are seed specific promoters. Useful promoters for seed specific expression are the USP promoter, preferably the long (Zakharov et al., 2004, J EΞxp Bot 55: 1463-71 ) or the short USP promoter (Baumlein etal., 1991 , MoI Gen Genet 225: 459-67). Other promoters which can be used in the present invention are the NOS-promoter, the Viάlin promoter, the Phaseolin promoter, the
Actin promoter, the Arcelin promoter, the Hordein promoter (Brandt et al., 1987, Carlsberg Res Commun 50: 333-45) and the Napin promoter, the ACP promoter as well as the FatB3- and FatB4 promoters, the 35S RNA promoter of the Cauliflower Mosaic Virus, the Ubiquitin promoter from maize, or the LeB4 promoter. The following publication summarizes most of the useful promoters: (Zakharov et al., 2004, J EΞxp Bot 55: 1463-71 ). Useful promoters for the expression in microorganisms are e.g. the lac operon promoter, the T3/T7 promoter, and the AOX promoter.
These promoters are well known to a person skilled in the art of molecular biology. In any case the skilled person can find suitable promoters in the literature, e.g. in relevant scientific journals and gene databases, or can isolate them from any desired organism using standard methods. Leader sequences may also be introduced into the vector, e.g. in order to achieve secretion of the polypeptides of the present invention into the medium. For example, the amino acid sequence "EEAYA" is a cleavage site at the C terminus of a leader sequence. The "KDEL" sequence at the C terminus of a polypeptide sequence is an endoplasmatic reticulum (ER) retention signal in plants. The invention also relates to a host cell comprising the polynucleotide, the vector and/or the polypeptide and/or the antibody construct. The host cell can be a prokaryotic or an eukaryotic cell; preferred is a host cell selected from the group comprising a bacterial cell, a yeast cell, a fungus cell, an algae cell and/or a plant cell. Especially preferred is a host cell selected from the group comprising an Escherichia coli cell, a Streptomyces cell, a Pichia pastoris cell, a Schizosaccharomyces cell, an Aspergillus cell, a Chlamydomonas cell, a Nicotiana spec, cell, a Pisum sativum cell, a Hordeum vulgare cell, a Zea mays cell, a rapeseed cell, a Cucumis sativus cell, and/or a LJnum usitatissimum cell. Preferably, the host cells are stably or transiently transformed with the above-described vectors of the present invention.
In another preferred embodiment the invention relates to a transgenic plant, parts thereof and/or microorganisms, containing the polynucleotide, the nucleic construct, the vector and/or the polypeptide of the present invention. As used herein, the term "transgenic" refers to cells, cell cultures, organisms, bacteria, fungi, animals, plants and progeny of any of the preceding, which have received foreign or modified nucleic acid sequence.
Preferably, the host cells or the plants or plant parts or microorganisms of the present invention express and synthesize the antigen-binding polypeptide and/or the antibody construct of the present invention. These host cells may be any prokaryotic or eukaryotic cells, preferably microorganismic cells or plant cells, more preferably bacterial, yeast, fungus, algae and plant cells. Most preferred among the microorganismic cells are Escherichia coli cells, Streptomyces cells, Pichia pastoris cells, Schizosaccharomyces cells, especially Schizosaccharomyces pombe cells, Aspergillus cells, and Chlamydomonas cells.
The plant cells and plants of the present invention may be in principle any plant cells or plants. Preferably, it is a monocotyledonous or dicotyledonous crop plant and more preferably a fodder plant. The most preferred plants are a Nicotiana spec, especially Nicotiana benthamiana and Nicoϋana tabacum, Pisum sativum, Hordeum vulgare, Zea mays, Cucumis sativus and Linum usitatissimum and rapeseed. Other plants which may be used are e.g. flax, poppy, olive, cocoa, barley, wheat, almond, sesame, mustard, castor oil plant, sunflower, soybean, peanut, coconut, turnip seed, cotton, cucumber, tobacco and oil palm trees.
The use of peas (pisum sativum) showed surprising results. Self pollinating plants like pisum sativum are especially suited for the production of recombinant proteins. The invention also relates to propagation material and agricultural products of the plants according to the invention, for example fruits, seeds, tubers, rootstocks, seedlings, cuttings and the like.
Especially the use of seeds is advantageous. The antibody constructs are protected from degradation due to protease inhibitors, which are present in most seeds. Therefore long-term storage does not influence the activity or the amount of protein. It is another object of the invention to provide a composition comprising the antigen-binding polypeptide, the polynucleotide, the nucleic construct and/or the antibody construct of the present invention and an acceptable excipient, carrier, buffer and/or stabilizer.
Antigen-binding polypeptides in the state of art may be degraded rapidly after oral application. Therefore special attention has to be given to the high acidity in the stomach as well as the presence of secretory proteases, particularly in the oral cavity and in the small intestine. Therefore the exάpient carrier, buffer and/or stabilizer preferably comprises a protein source, such as BSA, milk powder and/or pea flour. The proteins may be added alone or as a protein mixture. Additionally or alternatively, the excipient, carrier, buffer and/or stabilizer may comprise methyl-cellulose.
Furthermore, the antigen binding peptides may be formulated as acid-resistant micro-particles, or be packed into acid- resistant capsules, preferably gelatine capsules. This embodiment is especially advantageous for oral administration. Especially preferred is the composition, wherein the excipient, carrier, buffer and/or stabilizer comprises a protein source, preferably BSA, milk powder and/or pea flour; micro-particles and/or gelatine capsules. The invention also relates to the use of the polypeptide, the antibody construct, the polynucleotide, the nucleic construct and/or the vector for the manufacture of a medicament for the treatment diagnosis and/or prevention of infections, preferred infections associated with Emeria species, especially Emeria tenella.
In certain applications, the pharmaceutical compositions disclosed herein may be delivered via oral administration to an animal and/or a human. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent such as com starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or Saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. A syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations. In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally. Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous Solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable Solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium Chloride.
Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous Solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure.
For example, one dosage may be dissolved in 1 ml of isotonic NaCI solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some Variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety and purity standards as required by national or regional Offices of biologies Standards.
Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
In the case of sterile powders for the preparation of sterile injectable Solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethyiamine, histidine, procaine and the like. Upon formulation, Solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in injectable Solutions, drug-release capsules, and the like.
As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifingal agents, isotonic and absorption delaying agents, buffers, carrier Solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid Solutions or suspensions; solid forms suitable for solution in, or Suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.
Also preferred is the use of the plants, plant parts and/or microorganisms as fodder, preferred for production animals, more preferred birds, more preferred poultry, especially preferred chicken. Oral administration of antibodies specific to host pathogens is an attractive approach to establish protective immunity, especially against gastrointestinal pathogens. It is understood that the oral administration is not limited to production animals but can also be applied to humans.
This embodiment simplifies the administration in an immense way. Due to the invention production animals can be treated without the need of a special administration step. Surprisingly the fodder can be used in prophylaxis as well. One advantage of the invention is the fact that there is no toxic dose for the polypeptides of the invention. Therefore the administration via fodder is possible. This method saves a lot of time and costs, because no extra steps are necessary and a surprisingly high rate of yield was achieved.
Another advantage of this method is the fact that no isolation or purification of the antigen-binding peptide or antibody construct is necessary. In antibody production the isolation and purification is a time-consuming step and therefore expensive.
It was not expected, that the antigen-binding polypeptides or the antibody constructs of the invention show similar results when they are not isolated but administered in plants, parts thereof or microorganisms. Therefore it was surprising that the animals treated with fodder instead of purified antibodies showed comparable results. The teachings of the present invention are characterised by the following features: departure from the beaten track a new perception of the problem - satisfaction of a long-felt need or want hitherto all efforts of experts were in vain the simplicity of the solution, which proves inventive action, especially since it replaces a more complex doctrine the development of scientific technology followed another direction the achievement forwards the development - misconceptions among experts about the solution of the according problem (prejudice) technical progress, such as: improvement, increased performance, price-reduction, saving of time, material, work steps, costs or resources that are difficult to obtain, improved reliability, remedy of defects, improved quality, no maintenance, increased efficiency, better yield, augmentation of technical possibilities, provision of another product, opening of a second way, opening of a new field, first solution for a task, spare product alternatives, possibility of rationalisation, automation or miniaturisation or enrichment of the pharmaceutical fund special choice; since a certain possibility, the result of which was unforeseeable, was chosen among a great number of possibilities, it is a patentable lucky choice error in citations young field of technology - combined invention; a combination of a number of known elements, with a surprising effect licensing praise of experts and commercial success Said advantages are shown especially in the preferential embodiments of the invention.
Examples
Example 1 : Analyses of antigen binding Antigen: oocyst extract
The results of this experiment, shown in figure 1 , prove that Di-kappa-bodies are bivalent.
During experiments comparing scFV-Fc fragments, scFv antibody fragments and the Di-kappa-bodies of the present invention, it became apparent that the scFV-Fc fragments were unstable in comparison to the other constructs, making them difficult to analyse.
Example 2: Comparison of chicken and piglet chymes Method:
Purified antibody fragments were incubated at 37°C for 30 min with serial dilutions of piglet or chicken chyme. Antigen- binding activity was tested by ELISA.
Origin of used intestinal chyme
ED50: effective dilution of chime leading to 50% loss of activity
R2: goodness of fit
Results are shown in figure 2.
Example 3: Amino acid sequences of various polypeptide domains- Table 1 : Individual amino acid sequences of VH CDR1 , VH CDR2 and VH CDR3 of the Eimeria-binding polypeptides AA19, AA28, AB09, AB21 , AB28 and AD10.
Individual amino acid sequences of VL CDR1 , VL CDR2 and VL CDR3 of the Eimeria-binding polypeptides AA19,
AA28, AB09, AB21 , AB28 and AD10.
Example 4: Analysis of Molecular forms.
Size exclusion chromatography using FPLC was earned out to ascertain the molecular forms of the Di-kappa-bodies of the present invention. This chromatography analysis revealed that dimers are formed at a high frequency, of approximately 50%.
Example 5: Generation of Di-kappa constructs against various targets.
To represent the general validity and applicability of the invention, multiple examples have been selected and Dikappa constructs generated (Table 1 ).
Table 1. ScFv-Di-Ck constructs from ScFv and monoclonal antibodies (2G12, 2F5).
All the constructs accounted for were either transiently or stably expressed in N. benthamiana, or N. tabacum. In every case, good expression and proteins of the expected size were detected. In the case of anti ABA-ScFv, there are results which indicate an enhanced affinity. The Di-Ck constructs for ScFv directed against viral RNA polymerase also possess an enhanced biological activity in comparison to the original ScFv.
Claims
1. An antibody construct, comprisingtwo polypeptide monomers, each comprising one constant light domain, wherein the constant domains of both monomers are operatively connected, preferred via a disulfide bond, one variable light domain, wherein the variable light domain is connected to the constant light domain, one variable heavy domain, wherein the variable heavy domain is connected to the variable light domain via a linker, wherein said linker consists of 0-12 amino acids, whereby the variable light domain of each monomer is operatively associated with the variable heavy domain of the other monomer, and the variable light domain of each monomer forms an antigen binding site with the variable heavy domain of the other monomer.
2. A polypeptide, preferred according to claim 1 , comprising two constant domains of a light chain and two single chain variable fragments, comprising a variable domain of a light chain, a variable domain of a heavy chain and - a linker, wherein said linker consists of 0-12 amino acids, and is interposed between the variable light domain and the variable heavy domain, and each variable domain of a light chain forms an antigen binding site with the variable domain of a heavy chain of the other single chain variable fragment, wherein each single chain variable fragment is associated with a constant domain of a light chain.
3. An antibody construct, preferred according to claims 1 or 2, comprising two constant domains of a light chain, wherein the two constant domains of a light chain are operatively connected, preferred via a disulfide bond, two variable domains of a light chain, wherein each variable domain of a light chain is associated with a constant domain of a light chain, two variable domains of a heavy chain, wherein each variable domain of a heavy chain is connected to a variable domain of a light chain via a linker, wherein said linker consists of 0-12 amino acids.
4. An antibody construct, preferred according to claims 1 to 3, comprising two monomers, each comprising one constant light domain, wherein the constant domains of both chains are operatively connected, preferred via a disulfide bond, one variable light domain, wherein the variable light domain is associated with the constant domain, one variable heavy domain, wherein the variable heavy domain is connected to the variable light domain via a linker, wherein said linker consists of 0-12 amino acids, whereby the variable light domain of each chain is operatively associated with the variable heavy domain of the other chain.
5. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein the polypeptide and/or an antibody construct binds to and/or neutralizes or ameliorates the pathogenic effects of a pathogen, preferred Eimeria, Eimeria tenella, HIV, Hepatitis B, SARS coronavirus, Mycobacterium tuberculosis and/or Mycobacterium leprae.
6. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein both constant domains of a light chain are kappa domains.
7. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein both constant domains of a light chain are lambda domains.
8. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein the constant domains are connected, preferred via a disulfide bridge and/or hydrophobic interaction.
9. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein said polypeptide and/or an antibody construct is monospecific.
10. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein said polypeptide and/or an antibody construct is bispecific.
11. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein said linker is selected from the group consisting of a GS-linker, a yoNinker and/or a linker with the amino acid sequence comprising Seq. ID NO 41.
12. A polypeptide and/or an antibody construct according to any of the preceding claims, comprising the amino acid sequence of Seq. ID N0 1 , Seq. ID NO 2 and/or Seq. ID NO 3.
13. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a heavy chain VH comprises the amino acid sequence selected from the group comprising Seq. ID NO 4, Seq. ID NO 5 and/or Seq. ID NO 6.
14. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a light chain VL comprises the amino acid sequence selected from the group comprising Seq. ID NO 7, Seq. ID NO 8 and/or Seq. ID NO 9.
15. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one constant domain of a light chain Q. comprises the amino acid sequence of Seq. ID N0 10.
16. Use of a polypeptide and/or an antibody construct of any one of claims 1 to 15 for the manufacture of a medicament for the treatment, diagnosis and/or prevention of infections, preferred infections associated with HIV, SARS coronavirus, Mycobacterium tuberculosis and/or Mycobacterium leprae, Hepatitis B, Emeria species, especially Emeria tenella.
17. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a heavy chain VH comprises a VH CDR1 , wherein VH CDR1 comprises an amino acid sequence selected from the group comprising Seq. ID N0 11 , Seq. ID N0 12, Seq. ID NO 13, Seq. ID N0 14, Seq. ID N0 15 and/or Seq. ID N0 16.
18. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a heavy chain VH comprises a VH CDR2, wherein VH CDR2 comprises an amino acid sequence selected from the group comprising Seq. ID N0 17, Seq. ID N0 18, Seq. ID NO 19, Seq. ID NO 20, Seq. ID NO 21 and/or Seq. ID NO 22.
19. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a heavy chain VH comprises a VH CDR3, wherein VH CDR3 comprises an amino acid sequence selected from the group comprising Seq. ID NO 23, Seq. ID NO 24, Seq. ID NO 25, Seq. ID NO 26 and/or Seq. ID NO 27.
20. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a light chain VL comprises a VL CDR1 , wherein VL CDR1 comprises an amino acid sequence selected from the group comprising Seq. ID NO 28, Seq. ID NO 29, Seq. ID NO 30 and/or Seq. ID NO 31.
21. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a light chain VL comprises a VL CDR2, wherein VL CDR2 comprises an amino acid sequence selected from the group comprising Seq. ID NO 32 Seq. ID NO 33, Seq. ID NO 34 and/or Seq. ID NO 35.
22. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein at least one variable domain of a light chain VL comprises a VL CDR3, wherein VL CDR3 comprises an amino acid sequence selected from the group comprising Seq. ID NO 36, Seq. ID NO 37, Seq. ID NO 38, Seq. ID NO 39 and/or Seq. ID NO 40.
23. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein said linker is not susceptible to protease cleavage.
24. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein the polypeptide and/or an antibody construct is a non-immunoglobulin polypeptide.
25. A polypeptide and/or an antibody construct according to any of the preceding claims, wherein the polypeptide and/or an antibody construct binds to Eimeria, preferred Eimeria tenella, HIV, Hepatitis B,
SARS coronavirus, Mycobacterium tuberculosis and/or Mycobacterium leprae.
26. A polypeptide and/or an antibody construct according to any of the preceding claims, which neutralizes or ameliorates the pathogenic effects of a pathogen, preferred Eimeria and/or HIV, Hepatitis B, SARS coronavirus, Mycobacterium tuberculosis and/or Mycobacterium leprae.
27. A polypeptide and/or an antibody construct according to any of the preceding claims, which interferes with invasion, establishment or propagation of Emeria species in birds, preferred poultry, more preferred chicken.
28. A polynucleotide comprising a nucleotide sequence which encodes a polypeptide and/or an antibody construct of any one of the preceding claims.
29. A nucleotide construct comprising a polynucleotide of the preceding claim, wherein said polynucleotide is operably linked to a promoter that drives expression in a host cell.
30. A vector comprising the polynucleotide of claim 28 and/or the nucleotide construct of claim 29.
31. The vector of the preceding claim , wherein the vector is a phage display vector, a bacterial expression vector, a yeast expression vector, a fungus expression vector, an algae expression vector or a plant expression vector.
32. A host cell comprising the polynucleotide of claim 28, the nucleotide construct of claim 29, the vector of any one of the claims 30 or 31 and/or a polypeptide and/or an antibody construct of the claims 1 to 27.
33. The host cell of the preceding claim, wherein the host cell is selected from the group comprising a bacterial cell, a yeast cell, a fungus cell, an algae cell and/or a plant cell.
34. The host cell according to any of the preceding claims, which is selected from the group comprising an Escherichia coli cell, a Streptomyces cell, a Pichia pastoris cell, a Schizosaccharomyces cell, an Aspergillus cell, a Chlamydomonas cell, a Nicoϋana spec, cell, a Pisum sativum cell, a Hordeum vulgare cell, a Zea mays cell, a rapeseed cell, a Cucumis sativus cell, and/or a LJnum usitatissimum cell.
35. A transgenic plant, parts thereof and/or microorganisms, containing the polynucleotide of claim 28, the nucleic construct of claim 29 and/or a vector of any one of the claims 30 or 301.
36. A composition comprising the polynucleotide of claim 28, the nucleic construct of claim 29, a polypeptide and/or an antibody construct of any one of claims 1 to 27 and an acceptable excipient, carrier, buffer and/or stabilizer.
37. A composition according to the preceding claim, wherein the excipient carrier, buffer and/or stabilizer comprises a protein source, preferably BSA, milk powder and/or pea flour micro-particles and/or gelatine capsules.
38. Use of a polypeptide and/or an antibody construct of any one of claims 1 to 27 for the manufacture of a medicament for the treatment, diagnosis and/or prevention of infections, preferred infections associated with
Eimeria species, especially Eimeria tenella.
39. Use of the plants, plant parts and/or microorganisms of claim 35 as fodder, preferred for birds, more preferred poultry, especially preferred chicken.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008050749.0 | 2008-10-06 | ||
DE102008050749 | 2008-10-06 | ||
DE102008050757.1 | 2008-10-07 | ||
DE102008050757 | 2008-10-07 | ||
EP08075893.1A EP2172481B1 (en) | 2008-10-06 | 2008-11-20 | Proteolytically stable antibody formats |
EP08075893.1 | 2008-11-20 | ||
EP09075261 | 2009-06-09 | ||
EP09075261.9 | 2009-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010040545A1 true WO2010040545A1 (en) | 2010-04-15 |
Family
ID=41665504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/007277 WO2010040545A1 (en) | 2008-10-06 | 2009-10-06 | Proteolytically stable antibody formats |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010040545A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061618A1 (en) * | 1999-04-13 | 2000-10-19 | University Of Toronto | Fab-EPITOPE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING MONOCLONAL ANTIBODY 2F5 |
WO2003017780A1 (en) * | 2001-08-27 | 2003-03-06 | Advanced Bionutrition Corporation | Delivery of disease control in aquaculture and agriculture using nutritional feeds containing bioactive proteins produced by viruses |
WO2003087324A2 (en) * | 2002-04-09 | 2003-10-23 | Children's Hospital, Inc. | Antibody gene transfer and recombinant aav |
WO2005082004A2 (en) * | 2004-02-24 | 2005-09-09 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies having a domain-exchanged scaffold |
-
2009
- 2009-10-06 WO PCT/EP2009/007277 patent/WO2010040545A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061618A1 (en) * | 1999-04-13 | 2000-10-19 | University Of Toronto | Fab-EPITOPE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING MONOCLONAL ANTIBODY 2F5 |
WO2003017780A1 (en) * | 2001-08-27 | 2003-03-06 | Advanced Bionutrition Corporation | Delivery of disease control in aquaculture and agriculture using nutritional feeds containing bioactive proteins produced by viruses |
WO2003087324A2 (en) * | 2002-04-09 | 2003-10-23 | Children's Hospital, Inc. | Antibody gene transfer and recombinant aav |
WO2005082004A2 (en) * | 2004-02-24 | 2005-09-09 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies having a domain-exchanged scaffold |
Non-Patent Citations (6)
Title |
---|
HAYDEN M S ET AL: "SINGLE-CHAIN MONO- AND BISPECIFIC ANTIBODY DERIVATIVES WITH NOVEL BIOLOGICAL PROPERTIES AND ANTITUMOUR ACTIVITY FROM A COS CELL TRANSIENT EXPRESSION SYSTEM", THERAPEUTIC IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBL. LONDON, GB, vol. 1, no. 1, 1 January 1994 (1994-01-01), pages 3 - 15, XP009023719, ISSN: 0967-0149 * |
ILL C ET AL: "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10, no. 8, 1 August 1997 (1997-08-01), pages 949 - 957, XP002110047, ISSN: 0269-2139 * |
LU DAN ET AL: "Di-diabody: A novel tetravalent bispecific antibody molecule by design", JOURNAL OF IMMUNOLOGICAL METHODS,, vol. 279, no. 1-2, 1 August 2003 (2003-08-01), pages 219 - 232, XP002542445 * |
RAATS J M H ET AL: "Recombinant antibody expression vectors enabling double and triple immunostaining of tissue culture cells using monoclonal antibodies", EUROPEAN JOURNAL OF CELL BIOLOGY, WISSENSCHAFLICHE VERLAGSGESELLSCHAFT, STUTTGART, DE, vol. 84, no. 4, 22 April 2005 (2005-04-22), pages 517 - 521, XP025312756, ISSN: 0171-9335, [retrieved on 20050422] * |
WALLACH M ET AL: "Passive immunization of chickens against Eimeria maxima infection with a monoclonal antibody developed against a gametocyte antigen.", INFECTION AND IMMUNITY FEB 1990, vol. 58, no. 2, February 1990 (1990-02-01), pages 557 - 562, XP002543155, ISSN: 0019-9567 * |
WU A M ET AL: "Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 12, 1 January 2001 (2001-01-01), pages 1025 - 1033, XP002982160, ISSN: 0269-2139 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yusibov et al. | Antibody production in plants and green algae | |
US11339210B2 (en) | Anti-C5 antibodies and methods of treating complement-related diseases | |
EP2791169B1 (en) | Compounds and methods for treating inflammatory diseases | |
Merlin et al. | Comparative evaluation of recombinant protein production in different biofactories: the green perspective | |
EP1799813B1 (en) | System and method for production of antibodies in plant cell culture | |
US8663950B2 (en) | Production of a monoclonal antibody therapeutic against west nile virus in plants | |
US20140112927A1 (en) | Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration | |
CN109053892B (en) | Monoclonal antibody specifically binding to human and monkey CD38 antigens, and preparation method and application thereof | |
EP2172481B1 (en) | Proteolytically stable antibody formats | |
CA3128793C (en) | Method of producing a binder-toxin fusion protein in a plant cell or a whole plant | |
Chen | Development of plant-made monoclonal antibodies against viral infections | |
Komarova et al. | Plant-made antibodies: properties and therapeutic applications | |
US10982221B2 (en) | Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection | |
Moore et al. | Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants | |
Lotter-Stark et al. | Plant made anti-HIV microbicides—a field of opportunity | |
WO2010040545A1 (en) | Proteolytically stable antibody formats | |
JP7405139B2 (en) | bispecific antibody | |
WO2017156423A2 (en) | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever | |
US20150110812A1 (en) | Production of HER Receptor Antibodies in Plant | |
EP4196593A1 (en) | Recombinant immunotoxin comprising a ribotoxin or rnase | |
Dent | Development of a lectin-Fc fusion protein with antiviral and anti-cancer activity. | |
Pätz | Expression and characterisation of biopharmaceuticals in heterologous expression systems | |
Sheedy et al. | Plant-derived antibodies: the medicines of tomorrow | |
He et al. | Generation and Analysis of Novel Plant-Derived Antibody-Based Therapeutic Molecules against |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09744617 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09744617 Country of ref document: EP Kind code of ref document: A1 |